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Soy isoflavones are proposed to have certain health protective activities, including 
prevention of cancer, lowering blood cholesterol levels and reducing postmenopausal bone 
loss. To evaluate the health-enhancing properties of isoflavones, a stable and inexpensive 
source of these compounds is necessary. Chemical synthesis is a practical way to obtain pure 
isoflavones. The synthesis of daidzein was modified to a simple, fast and high yield method 
by cyclizing 2,4,4'-trihydroxydeoxybenzoin (THB) with boron trifluoride etherate and 
methanesulphonyl chloride. The yield was >86%, and the piunty of synthesized daidzein was 
>98%. The intermediate of daidzein synthesis, THB, with a similar structure to the 
isoflavones. proved to be an excellent internal standard in soy isoflavone analysis. 
The estrogenic activity of glycitein was investigated by using in vivo mice uterine 
enlargement assay and in vitro estrogen receptor (ER) binding assay. Glycitein demonstrated 
an estrogenic response in mice uterine enlargement assay 3 times greater than genistein, but 
30,000 times less than diethylstillbestrol (DES). Glycitein bound to mice uterine cytosol 
estrogen receptor proteins with an affinity similar to daidzein but 20 times lower than 
genistein. This is the first report demonstrates that glycitein has estrogenic activity 
comparable to daidzein and genistein. Glycitein, although only accounts for 5 to 10% of the 
total isoflavones in soybeans, can not be neglected in evaluating isoflavones" health 
enhancing properties and in development of isoflavone database in foods. 
The dietary effects of soy protein, with or without isoflavones. daidzein and soygerm 
on plasma cholesterol levels were investigated in golden Syrian hamsters. Daidzein. 
soygerm or soygerm extract, when added to casein diet. lowered plasma total cholesterol by 
15% to 28% (P<0.01) and LDL-cholesterol by 15 to 50% (P<0,01) in both male and female 
hamsters compared with the casein control group. Soy protein and isoflavone-depleted soy 
protein, when compared with the casein control, significantly lowered total cholesterol 
(P<0.01) and LDL-cholesterol (P<0.01) levels for both genders. These data suggest that the 
isoflavone daidzein. soygerm and soy protein with or without isoflavones. have the abilit\' to 
lower plasma cholesterol levels in hamsters. 
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GENERAL INTRODUCTION 
A. Introduction 
Soybeans contain significant amounts of isoflavones at 1-3 mg/g. Three types of 
isoflavones are found in soybeans: daidzein. genistein. and glycitein. These isoflavones 
predominantly occur as glucoside forms in soybeans. The isoflavones have been associated 
with different health-enhancing properties such as prevention of breast and prostate cancers; 
lowering blood cholesterol levels, thus, decreasing the risk of cardiovascular diseases; 
prevention of bone resorption and reduction of postmenopausal symptoms such as hot flash. 
The need to perform studies on isoflavone's possible health-enhancing properties 
requires an inexpensive, stable source of pure isoflavones. However, commercial isoflavones 
are very expensive and from limited sources. Isolation of isoflavones from soybeans is time 
consuming and provides very low yields. Chemical synthesis is a practical way to produce 
large quantity of pure isoflavones. To develop a simple, fast and high yield protocol to 
synthesize isoflavones is one important objective of my research. 
In order to fully and safely utilize the health-enhancing properties of soy isoflavones. 
a database of isoflavone content of soy products is needed. Development of a database of 
isoflavones in foods requires accurate and precise evaluation of different food systems. 
Usually a good internal standard is required to perform recovery studies and quality control. 
Selection of an appropriate internal standard and performance of quality control during the 
database development is another objective of my research. 
Numerous studies have been performed on the isoflavones. daidzein and genistein. 
They have weak estrogenic activity, which may be associated with their health-enhancing 
properties. In addition, genistein is a specific inhibitor of protein tyrosine kinase, a critical 
enzyme in cellular signal transduction and cellular proliferation. Genistein inhibits the 
activity of DNA topoisomerase II. an enzyme that is very important in DNA replication and 
cell proliferation. The antioxidant activity of daidzein and genistein may contribute to their 
observed anticancer activities by relieving oxidative stress. However, no biological activity 
of glycitein has been reported to date. Because glycitein has similar strucmre to the other 
isoflavones. we hypothesize that it would have weak estrogenic activity comparable to 
daidzein and genistein. Therefore, one goal is to investigate the estrogenic activity of 
glycitein. 
The cholesterol-lowering effects of soy protein have been reported for more than 80 
years. Numerous studies have been carried out to confirm this observation and to elucidate 
the mechanisms of this hypocholesterolemic effect. Recent studies have been focused on the 
roles that soy isoflavones might play in this effect. Although several animal-feeding studies 
using soy isoflavone extract or isoflavone-free soy proteins suggested that soy isoflavones 
may be one of the major factors responsible for this hypocholesterolemic effect, no direct 
evidence has been provided. The final objective of my research is to use pure isoflavones to 
investigate the possible hypocholesterolemic effect of isoflavones. 
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B. Dissertation Organization 
This dissertation consists of a literature review and three papers. The first paper. 
*' Isoflavone analysis: new internal standard and quality control" has been accepted for 
publication in the .American Journal of Clinical Nutrition. The second paper. "Estrogenic 
activity of glycitein. a soy isoflavone". has been submitted to the Journal of .Agriculture and 
Food Chemistry and examines the estrogenic activity of glycitein using an in vivo mice 
uterine enlargement assay and an in vitro estrogen receptor binding assay. The third paper, 
entitled " Soy protein, with or without isoflavones. daidzein and soygerm lower plasma 
cholesterol levels in hamsters", will be submitted to the Journal of Nutrition. This paper 
investigates the cholesterol lowering effects of soy isoflavone daidzein. soygerm as well as 
isoflavone-depleted soy protein. The papers follow the format of the journals to which they 
have been or will be submitted. .A general conclusion chapter follows the three papers. 
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LITERATURE REVIEW 
A. Plant Sources and Analytical Chemistry of Isoflavones 
Flavonoids are phenolic compounds occurring widely in plants and almost ail plant 
tissues are able to synthesize flavonoids (Ho. 1992; Kuhnau, 1976). There are a wide variety 
of types with at least 2,000 different naturally occurring flavonoids. The basic structure of 
these compounds consists of two aromatic rings (A-ring and B-ring) linked by a three carbon 
aliphatic chain which is condensed to form a pyran ring or a furan ring (C-ring) (Figure 1). 
In many plants, flavonoids are present in high concentrations, suggesting that they 
may have very important roles in the life of plants. These functions may include activities as 
phytoalexins by inhibiting the action of invading microorganisms (Barz and Welle, 1992) 
and as specific molecular signals to other microorganisms that take part in symbiotic 
relationships with the plants (Phillips. 1992). Bradyrhizobiiim sp.. which forms root nodules 
on leguminous plants, are attracted to the plant when specific flavonoids and isoflavonoids 
are secreted from the plant roots. The root nodules containing the bacterium convert 
atmospheric nitrogen to ammonia that can be used directly by the plants. The fimctions of 
isoflavones in soybeans are as inducing compounds of nod genes in Bradyrhizobiiim 
japoniciini (Kosslak et al., 1990) and as precursors for inducible pterocarpan phytoalexin. 
glyceollin 1 - III, in soybeans (Ebel and Grisebach. 1988). 
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A. Flavone B. Isoflavone 
0 
C. Common isoflavone aglycones 
Compounds R1 R2 R3 R4 
Daidzein OH H H OH 
Genistein OH H OH OH 
Glycitein OH 0CH3 H OH 
Biochanin A OH H OH 0CH3 
Formononetin OH H H 0CH3 
Figure I. Chemical structures of flavone, isoflavone and isoflavone aglycones. 
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Isoflavonoids differ from other flavonoid compounds in that they have a rearranged 
15-carbon skeleton derived from 3-phenylchroman (Figure 1). The isoflavonoid family 
includes isoflavones, isoflavanones, isoflavans, pterocarpans, coumestans and rotenoids. 
They differ from each other in the oxidation level of the skeletal structures. Isoflavones have 
B ring joined at position 3 on the C-ring and not at position 2 as in flavones (Figure I). 
The common isoflavone aglycones include daidzein, genistein, glycitein, 
formononetin and biochanin A (Figure I). Unlike other flavonoid compounds, isoflavonoids 
have a very limited distribution in plants. Isoflavones are found primarily, and almost 
exclusively, in legumes. C. arietinum or chickpeas, mainly accumulate formononetin and 
biochanin A. The soybeans have the highest content, ranging from 1 to 3 mg/g (Wang and 
Murphy, 1994), of the isoflavones daidzein, genistein, glycitein and their glucosides of seeds 
consumed by humans. The aglycones, daidzein and genistein were first isolated and 
identified from soybean meal by Walter (1941). The third isoflavone in soybeans, glycitein, 
was first isolated by Nairn et al. (1973). However, in soybeans, these isoflavones are mainly 
present in the plant in conjugated from, principally with glucose residue linked through one 
or more of the phenolic groups. Kudou et a/. (1991) isolated and characterized nine P-
glucoside forms of isoflavones from soybean hypocotyl. They are daidzin. glycitin. genistin. 
6"-0-acetyl daidzin, 6"-0-acetyl glycitin, 6"-0-acetyl genistin, 6"-0-malonyl daidzin, 6"-0-
malonyl glycitin and 6"-0-malonyl genistin (Figure 2). Both acetylation and malonylation of 
isoflavones occurs at position 6 of the glucose moiety in soybeans. The malonylated 
glucosides were very heat labile. At 80 °C, the majority of the glucosides were converted to 
daidzin, genistin and glycitin (Kudou et al. 1991). Kudou et a/. (1991) reported that most of 
the soy isoflavones are concentrated in the hypocotyl and are four times higher concentrated 
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CH2OR 
HO \ OH 
Compounds R1 R2 R3 
Daidzin H H 
6'''-0-Malonyl daidzin COCH2COOH H 
6"-0-Acetyl daidzin COCH3 H H 
Genistin H H OH 
6"-0-Malonyl genistin COCH2COOH H OH 
6"-0-Acetyl genistin COCH3 H 0
 
X 
Glycitin H OCH3 
' 
H 
6"-0-Maionyl glycitin COCH2COOH OCH3 H 
6"-0-Acetyl glycitin COCH3 OCH3 H 
Figure 2. Chemical Structures of soy isoflavone glucosidic forms. 
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than in cotyledons. Glycitein and its glucoside derivatives are ahnost exclusively found in 
the hypocotyl. The conjugated forms of isoflavones can be transformed to aglycones or free 
isoflavones through enzymatic (P-glucosidase) or acidic (2 N HCl at 98 °C for 2 hours) 
hydrolysis (Franke er al.. 1994). 
Separation of isoflavones can be accomplished by using the following techniques; 
paper chromatography (PC), thin-layer chromatography (TLC), column liquid 
chromatography, reverse-phase high-performance liquid chromatography (HPLC) and gas 
chromatography (GC). The detection and identification of isoflavones can be achieved by 
using UV absorbency detection, mass spectrometry, coulometric array detection (CAD), IR 
and NMR analysis. 
Ultraviolet (UV) spectroscopy is very effective for the identification of isoflavones 
(Marbry et al., 1970). Since there is little or no conjugation between A- and B-rtngs of 
isoflavones, they typically exhibit an intense Band 11 absorption in the range of 245 - 270 nm 
with only a shoulder or low intensity Band I peak above 300 nm (Marbry et al., 1970) 
(Figure 3). Band II maximal absorption wavelength is relatively unaffected by increased 
hydroxylation of the B-ring. For example, 5,7-dihydroxyisoflavone has maximal Band II 
absorption at 259 nm and 5,7,4'-trihydroxyisoflavone (genistein) has maximal Band II 
absorption at 261 nm. However, Band II can be shifted bathochromicaily by increased 
oxygenation in the A-ring. For example, daidzein has maximal Band II absorption at 249 run, 
while genistein, with an additional 5-hydroxy group, has a maximum at 261 nm, and 6-
hydroxygenistein has a maximum at 270 nm. 
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§i 5CK43I tl.S7-H.14 
Band II 
Band I 
Figure 3. UV spectrum of glycitein from 200 to 350 nm. Band II maximal absorption at 262 
nm and band I maximal absorption at 323 nm. 
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Certain reagents, such as sodium methoxide (NaOMe), aluminum chloride (AICI3), 
HCI, sodium acetate (NaOAc) and boric acid, can be used to perform specific oxidation and 
cause UV spectral shifts for identification purposes with isofiavones. The spectra of 
isoflavones containing A-ring hydroxy! groups usually show bathochromic shifts on both 
Band I and Band II in the presence of NaOMe. In addition, the peaks in the LTV spectrum of 
a 3'4'-dihydroxyisoflavone show reduced intensity within a few minutes with added NaOMe. 
NaOAc specifically ionizes the 7-hydroxyl groups in isoflavones and causes Band II to show 
bathochromic shift of 6 - 20 nm, and can be used to detect the presence of 7-hydroxyl group. 
The detection of A-ring ortho-dihydroxyl groups can be done by the effects of AICI3 and 
AICI3 / HCI on the spectrum. When compounds contain ortho-dihydroxyl groups at position 
6,7 or 7.8, the AlCh spectrum exhibits bathochromic shifts with respect to the AICI3 /HCI 
spectrum. Band II of 5-hydroxyisoflavones undergoes a consistent 10-14 nm bathochromic 
shift compared to the spectrum in methanol in the presence of AICI3/HCI (Mabry et aL, 
1970). 
The extraction of isoflavones usually involves organic solvents. Methanol, ethanol, 
acetone and acetonitrile are the most widely used solvents. Because isoflavones are neither 
very hydrophilic nor very lipophilic, aqueous solutions of these organic solvents were used. 
Jones et al. (1989), Coward et al. (1993) and Eldridge et al. (1982) used 80% methanol. 
Nairn et al. (1973) and Seo et al. (1984) used 80% ethanol while Farmakalidis and Murphy 
(1985) used acetone-0.1 N HCI. Wang and Murphy (1994) used 70% aqueous acetonitrile + 
0.1 N HCI to extract isoflavones. In some procedures, pH was adjusted to achieve a better 
extraction efficiency (Murphy, 1981). Farmakalidis and Murphy (1985) compared the 
extraction of isoflavones from defatted soyflakes using acetone - O.IN HCI and using 80% 
II 
methanol. The extract of 80% methanol had much lower levels of acetyl-daidzin and acetyl-
genistin compared to acetone-HCl extract, while other major isoflavones including daidzin 
and genistin in the two extracts were at the same level. There was selective extraction of the 
isoflavones with 80% methanol. 
The most popular technique for isoflavone analysis is octadecylsilanes (Cis) reverse-
phase HPLC with UV detection. However, other methods, including TLC (Pratt and Birac, 
1979), PC (Knuckles et aL 1976), GC (Lu et aL 1995), GC-MS (Dwyer et ai. 1994), 
HPLC-MS (Barnes et aL, 1998) and HPLC-CAD (Gamache and Acworth, 1998) are 
employed in the analysis of isoflavones. UV detection works well for most soybean food 
samples, which have a relatively high content of isoflavones in the mg/g range. However, 
because of its detection limits at about 1.8 jiM in the injection solution, UV detector is not a 
very good tool for the analysis of biological samples such as urine and plasma, which 
containing levels of 0.1 to 10 |j,M in isoflavones. Mass-spectrometry has been used 
successfully with HPLC and GC to detect 0.1 to 10 (iM levels of isoflavones (Barnes et aL. 
1998; Dwyer et aL. 1994). Electrochemical detector has been successfully used to detect low 
levels of isoflavone with the detection limit of as low as 0.005 fiM (Gamache and Acworth, 
1998). 
There have been reports on the isoflavone content in different soybeans and soybean 
foods. Murphy (1982) used an HPLC method to analyzed the content of daidzein, daidzin, 
genistein and genistin in several processed soybean products, including toasted soy flakes, 
tofu, soy sprouts, soy isolate and soy sauce. The total isoflavone content ranged from zero in 
soy sauce to 1 mg/g in toasted soy flakes. Franke et aL (1994) used HPLC to quantify 
daidzein and genistein levels in more than 40 foods, mostly legumes. They used acid 
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hydrolysis to produce the free forms and only measured the total aglycones of daidzein and 
genistein. They used flavone as an internal standard to adjust for losses during the extraction 
and analysis. The recovery of the internal standard achieved was between 94% to 104%. 
Daidzein and genistein were detected in soybean seeds, soy flours and tofu at levels from 18 
Hg/g in soybean hulls to 2.2 mg/g in certain variety of dry soybeans. Wang and Murphy 
(1994) used HPLC method to analyze the isoflavone content in 29 commercial soybean 
foods, categorized into soy ingredients, traditional and second-generation soy foods. They 
analyzed all 12 isoflavone isomers, including glycitein and its glucosidic forms. E.xtemal 
standards daidzein and genistein were used to spike the sample to estimate recoveries. 
Recoveries of 70% to 100% were achieved in different food samples. In addition to 
individual isoflavone levels, they reported normalized total isoflavone content. .A.11 the 
glucosidic form concentrations of isoflavones were converted back to the concentrations of 
free forms by normalization of molecular weight differences. Simply adding concentrations 
of each individual forms will overstate the isoflavone content, since the sugar portion in 
glucosidic forms are counted in. Soy ingredients, except soy concentrate which has been 
alcohol washed during the processing, including soybeans, soy flour, soy granule, soy isolate 
and textured vegetable protein (TVP), had total normalized isoflavone content from 466 |ag/g 
to 1640 [ag/g. Traditional soy foods include tofli, soymilk, tempeh and miso, all had 
significant amount of isoflavones, ranging from 100 to 1600 !a.g/g. However, the second 
generation of soy products, such as soy hot dog, soy berger, soy bacon, had very low levels 
of isoflavone (<100 |J.g/g). The isoflavone composition of American and Japanese soybeans 
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in Iowa was studied by Wang and Murphy (1994). Total isoflavones ranged from 1176 fig/g 
to 3309 |J.g/g. Crop year seems to have great impact on total isoflavone content. 
Coward et al (1993) used 80% aqueous methanol (10 mL/g) to extract isoflavones 
from food samples and used HPLC-UV detection to analyzed the isoflavone content in 
soybean foods from American and Asian diets. The Asian soy foods tested, including 
soymilk, tofu, soy flour, soy powder and soy nuts, which were not diluted by the addition of 
non-soybean components, had total isoflavone content in the range of 1.3 to 3.8 mg/'g. 
Fermented soy foods, including tempeh, miso and soybean paste, had lower total content of 
total isoflavones. ranging from 0.6 to 1.4 mg/g. The commercial soy products used in 
.\merican foods, including soy floiu" and soy protein concentrate, had total isoflavone content 
from 1 to 2.7 mg/g. However, soy sauce had negligible amount of isoflavones. 
The isoflavone content in soy-based infant formulas was investigated by Setchell ei ul 
(1997). Five major brands of soy-based infant formulas, including Nursoy powdered formula 
(Wyeth Laboratories. Philadelphia, PA), Isomil powdered formula (Ross Products Division 
Abbott Laboratories. Columbus. OH), Isomil "Ready to Feed" liquid formula. Alsoy liquid 
formula concentrate (Carnation Nutritional Products Division. Nestle Food Company, 
Glendale, CA) and Prosobee liquid formula concentrate (Mead Johnson, Evansville. IN). 
were analyzed by HPLC method. All of the soy formulas contained mainly glycoside forms 
of genistein and daidzein, ranging from 32 to 47 n.g/mL of reconstituted formula. Murphy e[ 
al (1997) analyzed the isoflavone content in 6 major brands of soy-based infant formulas. In 
addition to the five soy-based formulas analyzed by Setchell et al (1997), Gerber's soy 
formula was analyzed. Total isoflavones in these formulas ranged from 214 to 285 |ig/g of 
dry formula and 25 to 30 jig/mL reconstituted formula. 
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Mazur et al. (1998) used GC-MS to analyze the isoflavone content in 48 cultivars of 
16 food legume species. The highest total concentration of isoflavones was found in kudzu 
root (over 200.000 |J.g/g), followed by soybeans (from 373 |j.g/g to 1410 fig/g) and chickpea 
(12 to 36 fig/g). 
Recently. Reinli and Block (1996) summarized 21 studies on isoflavone analysis and 
tried to create a phytoestrogen database in foods. Of the 21 studies re\aewed on isoflavone 
analysis, 17 studies used HPLC to measure isoflavones. others used either gas 
chromatography or thin-layer chromatography. Most of the studies only analyzed daidzein 
and genistein families. Wang and Murphy (1994) reported glycitein content in different food 
products, in addition to daidzein and genistein. The normalized total isoflavone content, 
including daidzein and genistein. in different soy foods varied from 1-2 ug/g to 2-3 mg/g. 
Because different researches used different extraction and analysis procedure, and only a few 
of them used internal standards to account for losses during the extraction and analysis 
process, the database set up by Reinli and Block showed inconsistency in the literature. 
To fully utilize the health promoting benefits of soy isoflavones. a complete database 
of isoflavone content in foods is needed. To build a good database of isoflavone content in 
foods, a systemic, standardized, and well-controlled analysis need to be carried out. The 
food samples should cover the mostly consumed soy products, the analysis method should be 
well recognized and widely tested, in addition, both internal and external standards are 
needed for a good quality control. 
15 
B. Sources of Isoflavone Standards: 
Isolation, purification and ctiemical synthesis 
To isolate milligrams of isoflavones from soybeans, column chromatography is a 
good choice. Defatted soybeans or soy flours are the common starting materials. Eight\' 
percent aqueous ethanol (Setchell et al.. 1987) or acetone-0.1 N HCl (Farmakalidis and 
Murphy, 1985) was used to extract isoflavones. The crude isoflavone fractions can be 
separated to individual pure isoflavones by fractionating through different column matenals 
including silica gel. Sephadex LH-20 and polyamide (Kudou et al.. 1991; Agarwal et al.. 
1984). Usually these column materials have to be used in sequential order to achie% e the 
isolation of pure isoflavones. The semi-preparative HPLC is a faster, simpler separation 
method, but requires extensive sample treatment before chromatography and has relatively 
lower capacity due to solubility limits of isoflavones (Farmakalidis and Murphy. 1984). 
Since the discovery of isoflavones. several methods have been introduced to 
chemically synthesize them. In many cases, deoxybenzoins and chalcones can ser\ e as the 
starting materials for natiural isoflavones. The synthesis of deoxybenzoin can be achieved by 
the Friedel-Crafts reaction of the phenylacetyl chloride and phenol, or the boron trifluoride 
catalyzed reaction of the phenol and the phenylacetic acid. Chalcones are readily obtained 
by the condensation of acetophenones and the aromatic aldehydes. The cyclization of 
deoxybenzoin can be achieved by a wide variety of Ci reagents such as ethoxallyl chloride 
(Iyer et al., 1989), ethyl formate (Shaw et al., 1990) and dimethyl formamide (DMF) (Parmar 
et al., 1987; Jain et al., 1986). Sometimes the protection of other functional groups, except 
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for the hydroxy! required to condense the C: ring may be necessary. The protective groups 
are then removed by acid hydrolysis. 
The chemical synthesis of isotlavones can be time-consuming and with low yields. 
However, Chang et al. (1994) reported the microwave-mediated synthesis of the isoflavones. 
daidzein. genistein, formononetin and biochanin .\. By using microwave energy', they 
reduced synthesis time. However, in their synthesis procedure for daidzein and 
formononetin. they had to use TLC purification to obtain pure isoflavones from the reaction 
mixture, which lowered the yield and increased the total operation time. 
Wahala ei al. (1995) successfully synthesized more than 20 different isoflavones. 
include daidzein and genistein. by using the "one-pot" procedure for deoxybenzoin and 
isoflavones. .A. phenol and an ar\'lacetic acid were dissolved into freshly distilled boron 
trifluoride etherate under argon. The mixture was stirred and heated at 65-70 °C. Then the 
mixtiu-e was cooled to room temperature and dr\' dimethylformamide (DMF) was added. 
The mixture was heated to around 50°C and methanesulphonyl chloride was added slowly. 
-\fter reaction at 60-70 °C. the reaction mi.xture was cooled down. Cold water was added to 
the mixtiare. the crude isoflavone was then recrystallized from aqueous methanol. The vield 
of daidzein and genistein was 98S'o & 53%, respectively. They demonstrated that deuteriiun 
(D) -labeled daidzein and genistein could be produced by using OR'OD e.xchange of 
phenolic groups in isoflavones. 
-A.lthough numerous methods have been reported on the chemical synthesis of 
daidzein and genistein. no method on glycitein synthesis was reported until early 1995. 
Nogradi and Szollosy (1995) have reported the synthesis of glycitein and its glucoside form, 
glycitin. Glycitein was prepared by oxidative rearrangement of the fully protected chalcone 
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by TI(N03 )3 in methanol, followed by deprotection and ring closure. The glucosylation of 
glycitein with acetobromoglucose and subsequent saponification yields glycitin. 
C. How Do Plants Make Isoflavones? 
The biosynthesis of isoflavones has been studies extensively in both chickpea and 
soybeans; thus, the essential enzymes of the general phenyl-propanoid pathway and chalcone 
synthase, chalcone isomerase as well as isoflavone synthase are well known (Braz et al., 
1990; Ebel et al.. 1986). It is clear that A-ring arises from acetate and the B-ring-C; unit 
may originate from various Cg precursors such as phenylalanine and caffeic acid (Birch. 
1957). Chalcone synthase, the key enzyme of isoflavone biosynthesis, catalyzes the 
formation of a chalcone with a phloroglucinol substitution pattern in ring A. The resulting 
6'-hydroxychalcone is isomerized to naringenin, the intermediate for genistein and biochamn 
A formation. A central step in isoflavone biosynthesis is the molecular rearrangement 
catalyzed by isoflavone synthase in which a {2S)-flavanone is converted to an isoflavone 
such as daidzein or genistein. 4'-0-Methylation. catalyzed by isoflavone methyltransferase, 
of daidzein yielding formononetin. of genistein yielding biochanin A (Wengenmayer et al., 
1974). These aglycons undergo further enzymatic glucosylation and malonylation to form 
the predominant glucoside forms of isoflavones in soybeans (Figure 4). 
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Figure 4. Biosynthesis pathway to isoflavone daidzein and genistein in soybeans. 
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D. Are Isoflavones Good Antioxidants? 
Soybeans, defatted soybean flours, soy protein concentrates and soy protein isolates 
have appreciable antioxidant activity in lipid-aqueous systems (Pratt and Birac, 1979). The 
antioxidant activity of fermented soybean products such as tempeh and natto was 
investigated by exposing the lipids in these samples to air and measuring the extent of lipid 
peroxidation and significant antioxidant activity was reported (Esaki et al. 1994). The 
antioxidant activity of these soy products was thought to be due to tocopherols, 
phospholipids, amino acids and peptides in soybeans, as well as isoflavones. The antioxidant 
activity of soybean isoflavones was demonstrated in in vitro systems by measuring the extent 
of inhibition of lipoxygenase (Naim et al., 1976) and by the Rancimat method with lard at 
100°C (Dziedzic and Hudson, 1983). The degree of the antioxidant capacity of isoflavones 
was thought to be positively correlated to the number of hydroxyl groups in the structure 
(Naim et al., 1976). Isoflavones, genistein, genistin, daidzein and daidzin at 10'" M inhibited 
linoleate oxidation 70%, 30%, 26% and 15%, respectively (Pratt and Birac, 1979). Genistein 
seems to have the greatest antioxidant activity among these isoflavones. 
Fleury et al. (1992) used Rancimat, storage test, heat and UV light-induced oxidation 
to test the antioxidant activity of malonyl isoflavones. No antioxidant activity was observed 
in the Rancimat test performed at 100°C and the heat-induced oxidation of P-
carotene/Iinoleic acid system. They suggested that isoflavones might not act as radical 
scavengers. However, malonyl isoflavones at 500 ppm have been shown to be good 
antioxidants in the storage test at 37°C and in UV light-induced oxidation of P-
carotene/linoleic acid system (Fleury et al. 1992). 
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There is considerable evidence to suggest that reactive oxygen species may induce a 
series of oxidative reactions which could cause modification of some macromolecules and 
lead to mutagenesis and carcinogenesis (Frankel, 1992). The antioxidant activity of 
isoflavones may contribute to their anticarcinogenic effects. Record et al. (1995) tested the 
antioxidant activity of genistein. Significant protection was observed on incubation of 
liposomes containing genistein in the presence of the peroxyl radical generating agent. 
Genistein gave 50% protection against UV- and peroxyl-induced lipid peroxidation in 
liposomes at about 25 nmole genistein/mg of phosphatidylcholine (PC). Other peroxidative 
systems, involving hydrogen peroxide, such as metmyoglobin peroxidase activity and 
Fe/ascorbate/hydrogen peroxide oxidation of liposomes, were inhibited by genistein. But 
genistein was ineffective in preventing conjugated diene formation in linoleic acid micelles. 
Wei et al. (1995) compared the effects of different isoflavones on the hydrogen peroxide 
production by tumor promoter activated HL-60 cells. dose-dependent effect was observed 
for the inhibition by these isoflavones. Among the tested compounds at concentrations of 10. 
50, 100 and 200 |j.M, genistein (IC5o= 25 |j.M) and daidzein (IC5o= 150 (iM) were the most 
potent inhibitors of hydrogen peroxide formation. In contrast, apigenin and biochanin A 
showed little inhibitory effect. They proposed that the hydroxyl group at 4' position is 
crucial for isoflavone antioxidant activity. 
Cai and Wei (1996) investigated the in vivo effects of genistein on antioxidant 
enzyme activities in SENCAR mice. Dietary administration of genistein at 50 or 250 ppm in 
diets for 30 days significantly increased the activities of antioxidant enzymes such as 
catalase, superoxide dismutase and glutathine peroxidase in liver, kidney, lung and intestine 
of the SENCAR mice compared to groups receiving no genistein. 
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Although antioxidant activities have been reported for genistein and daidzein, the 
isoflavone concentrations used in most of the systems are in the range of 50 fiM to Im M, 
which are well above the physiological concentrations, which are 0.1 to 10 |j.M. The 
antioxidant activities achieved by isoflavones, in most of the cases, were lower than some of 
the positive antioxidant controls, such as a-tocopherol. In addition, the highest physiological 
isoflavone concentration in human is probably around 10 [iM. So it is unlikely that the 
antioxidant activity of isoflavones explains some of their health enhancing properties. 
E. Estrogenic or Anti-estrogenic? 
The estrogens are a family of hormones synthesized in a variety of tissues that are 
required for the development of female secondary sex characteristics. 17-P-Estradiol is the 
primary estrogen of ovarian origin. In some species, estrone, synthesized in numerous 
tissues, is more abundant. Estrogens are formed by the aromatization of androgens in a 
complex process that involves three hydroxylation steps, each of which requires O2 and 
NADPH. The aromatase enzyme complex is the key enzyme in estrogen synthesis, and 
estradiol is formed from testosterone, whereas estrone results from the aromatization of 
androstenedione. These estrogens are produced in the ovary, adipose and muscle tissues, and 
liver. Women cease having regular menstrual cycles at about age 46 to 53, coincident with 
loss of all follicles and ovarian estrogen production. Estrone, a weak estrogen, is produced in 
postmenopausal women as the principal estrogen, whereas in premenopausal women, 
estradiol is the major estrogen. The loss of estrogen production in postmenopausal women is 
thought to be the main reason for accelerated bone resorption causing osteoporosis, which 
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can be a major health problem in older individuals. In addition, the loss of estrogen increases 
total cholesterol, LDL cholesterol and triglycerides, and decreases HDL cholesterol (Kannel 
et al., 1976; Gaspard et al., 1995). Over the years, life expectancy of women has increased 
dramatically, while the average age of menopause has remained relatively stable. As a result, 
women today will spend more than one third of their lives beyond menopause (Burnett, 
1987) with a natural estrogen deficit and with greater risk of health problems such as 
osteoporosis and heart diseases. To treat these problems, certain natural or synthetic 
estrogenic compounds have been used as estrogen replacements. 
A number of chemicals in the environment possess estrogenic activity in a variety of 
biological systems. These compounds are capable of perturbing the normal hormonal 
melieu in human and animals. They may exhibit their endocrine and reproductive effects 
through: 1) mimicking the effects of endogenous hormones such as estrogens; 2) 
antagonizing the effects of normal endogenous hormones; 3) altering the pattern of synthesis 
and metabolism of natural hormones; and 4) modifying hormone receptor levels. These 
compounds include plant products such as isoflavonoids and fungal products such as 
zcaralenone; pesticides such as DDT and dieldrin; plasticizers such as polyclorinated 
biphenyls (PCB); synthetic estrogenic agents administered to livestock such as 
diethylstilbestrol (DES), and a variety of other chemicals such as bisphenol A (Soto et al., 
1995). It is clear that pharmacological doses of estrogenic compounds, such as DES, can 
cause toxicity. For example, women exposed to DES in iitero developed reproductive tract 
abnormalities and endometrial cancers (Herbst et al., 1971). Chronic exposure to these 
environment estrogens may have adverse or beneficial effects on health. 
23 
With the growing awareness and concern regarding the estrogens in the environment, 
dependable biological assays for estrogenic activity are needed. One important issue is that 
various investigators use different endpoints to define estrogens. Some researchers require 
the growth of rat or mouse uterus to define estrogen bioactivity. Others rely on the ability to 
bind to estrogen receptors, while still others use the estrogen-dependent cell lines to test 
estrogenic activity. Recently, estrogen receptor-dependent transcriptional expression (Soto et 
al.. 1995) was used to evaluate estrogenicity. Between 1920 and 1996, numerous studies 
have been carried out to test the estrogenic activity of environmental compounds. These 
methods can be grouped into four categories: (I) reproductive tract response; 
(2) non-reproductive tract target tissue response; (3) estrogen receptor binding assay; and (4) 
estrogen receptor-dependent transcnptional expression (Reel et al., 1996). A possible test 
array for potential estrogenic/anti-estrogenic compounds is proposed by Reel et al. {1996). 
They propose the following decision tree. The first step is estrogen receptor binding assay 
{in vitro). A negative response means the compound is unlikely to be a direct acting estrogen 
and/or anti-estrogen. If the compoimd gives a positive response in the receptor-binding 
assay, the next step is the estrogen receptor-dependent transcriptional expression assay (in 
vitro). A negative response means the compound is a possible antagonist, a positive response 
suggests potential estrogen. The third step involves uterotrophic activity [in vivo) and 
vaginal comification (m vivo). A negative response from either of these test means the 
compound is unlikely to be estrogenic in vivo, while a positive response means the 
compound is estrogenic. 
Phytoestrogens include a wide variety of plant chemicals with weak estrogenic 
activity. Phytoestrogens have been identified in over 300 different plants (Bierman, 1992). 
These phytoestrogens vary widely in both estrogenic potency, physiological effects and may 
have both estrogen agonistic and antagonistic properties (Dwyer et al., 1994). The estrogen-
agonist and estrogen-antagonist effects depend, in part, on the ambient estrogen 
concentrations at the site of action (Anderson, 1996). Table 1 summarizes some of the best-
characterized phytoestrogens (Anderson, 1996). 
Isoflavones have similar structures as the natural estrogen, estradiol, and the synthetic 
estrogen, DES. (Figure 5). Genistein and daidzein are roughly 10^ times less effective than 
DES and estradiol in the mice uterine enlargement assay (Bickoff et al., 1962). Farmakalidis 
and Murphy (1985) used inbred B6D2FI mice to test the estrogenic responses of daidzin, 
genistin and genistein. The estrogenic response to 1.5 mg of genistin was equivalent to 1 mg 
of genistein or a 1:1 molar relationship in estrogenic activity between genistin and genistein. 
Daidzin had a relative potency of 40% of that of genistin. 
Animal species differ in their response to phytoestrogens. In sheep, daidzein, 
formononetin and their metabolite, equol, shows potent estrogenic activity in uterine 
enlargement assay. In contrast, genistein and biochanin A are much less potent 
(Braden et al., 1967). However, in mice and rats uterine growth assay, daidzein and 
formononetin were found to be much less potent than genistein (Bickoff et al., 1962). The 
response to phytoestrogen may differ within the same species, the Swiss CD-I mouse did not 
respond, and ICR mouse showed a slight response, to daidzein and genistein, while inbred 
B6D2F1 mouse showed significant responses to these phytoestrogens (Farmakalidis and 
Murphy, 1984). 
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Table 1. Major phytoestrogen classes, representative compounds and sources. 
Class Example Source Comments 
Isoflavone Genistein 
Daidzein 
Formononetin 
Biochanin A 
Legumes, mainly 
soybeans, chickpeas and 
cloves. 
Metabolized in body by human 
and other animals (rats, mice 
and sheep) to a senes products 
including equol. 
dihydrodaidzein, 
dihydrogenistem and 
O-desmethvlaneolensm 
Lignans Matairesinol 
Lariciresinoi 
Isolarciresinol 
Secoisolaricerison 
Seeds and Grains, such as Metabolized in humans to 
sesame seed and flaxseed. enterolactone, enterodiol and 
7-hydroxymatairesinol. 
Coumestans Coumestrol Legumes, includes alfalfa, 
clovers and soybean 
sprout 
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OH Natural estrogen ( Estradiol) 
HO 
Syntiietic estrogen (Diethylstilbestrol. DES) 
OH 
HO 
Soy isoflavones R1 R2 
Daidzein H H 
Genistein H OH 
Glycitein 0CH3 H 
.OH 
HO 
Figure 5. Structures of natural estrogen, synthetic estrogen and isoflavones. 
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Verdeal et al. (1980) compared the estrogen receptor (ER) binding affinity of 
different isoflavones using rat uterine cytosol preparation. Genistein had about 100 times 
lower binding affinity to ER than estradiol, but 15 times higher than daidzein and 20 times 
higher than biochanin A. The estrogen receptor binding assay was performed in rabbit 
(Shemesh, 1979), sheep (Shutt and Cox, 1972) and calf (Lee et al., 1977) uterine cytosol and 
human cancer cell line MCF-7 (Martin et al.. 1978). The binding affinity of genistein was 
between 50 to 160 times lower compared with that of estradiol. Daidzein was about 10 times 
lower than genistein in binding affinity. 
The effect of genistein on the estrogen receptor (ER) positive human breast cancer 
cell line MCF-7 has been investigated by Thomas et al. (1996). Genistein stimulated 
estrogen-responsive pS2 mRNA expression at concentration as low as 10 nM. Thus, it may 
act through an ER-mediated transcriptional event. When both genistein and estradiol were 
added together, the expression of pS2 mRNA was 20% lower than when estradiol was added 
alone. MCF-7 cells, treated with genistein, showed a decrease in the response to estrogen as 
well as a decrease in ER mRNA levels. In another study, genistein injected subcutaneously 
at a dose of 1.6 mg was shown to inhibit DES-stimuIated vaginal and uterine growth by 
almost 40% in rats (Messina et al, 1994). When 300 to 900 |j.g of genistein are injected into 
mice with estradiol, the uptake of estradiol by the uterus and vagina was significantly 
reduced by 71% and 90%, respectively (Folman et al, 1969). These results suggested that 
genistein interfered with the effects of estradiol and DES, and thus, has antiestrogeic activity. 
Estrogen can act through the classical ER, now called ERa. ERa is a 65-66 kJD 
protein possessing the following domains; an N-terminal portion (regions A/B) which 
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contains transactivation domains possessing constimtive and hormone-dqjendent 
transcription-activating flmctions. Region C is a DNA-binding domain with two "zinc-
finger" motifs in the middle. D is the hinge region and E is the area of high-affinity 
(hormone) ligand-binding domain in the C-terminal region. Ligand binding induces a 
conformational change in ERa and subsequent DNA binding to specific estrogen response 
elements (EREs) present in target genes. ERa then activates transcription initiation through 
protein ; protein interactions with accessory factors. The estrogen receptor knockout 
(ERKO) animals are good models to study the in vivo effects of estrogens through ER 
(Korach et al., 1994). For example, classic estrogen responses in the uterus such as water 
imbibition, hyperemia and gene induction are absent in the ERKO mice (Couse et al., 1995). 
Synthetic estrogen tamoxifen can also induce these responses in normal mice but is 
ineffective in ERKO mice. 
Experiments in ERKO mice have suggested that some estrogenic effects were not 
mediated solely by ERa. For example, progesterone receptor mRNA is induced in the 
preoptic area of ERKO mice by estrogen (Merchenthaier et al., 1996). This led to the recent 
cloning of a new ER, called ERp. by Kuiper et al. (1996). ERp is a member of the steroid 
hormone superfamily like ERa. ERP binds to estrogen with high affinity; it activates 
transcription in response to estrogen; and it is expressed in estrogen target tissues such as 
pituitary and uterus. ERP binds estradiol with a dissociation constant of 0.4 nM versus the 
0.1 nM of ERa under the same assay conditions (Kuiper et al.. 1997). In general, other 
estrogenic or antiestrogenic compounds, such as tamoxifen, do not discriminate between 
ERa and ERp. There is overlapping pattern of expression of ERp relative to ERa. ERp is 
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highly expressed in prostate and ovary with low expression in brain, uterus and testis 
(Messelman et al., 1996). The discovery of ERP raises important questions on the 
mechanisms of the actions of estrogen. The tissue distribution of ERa and ERp, and the 
differences in certain ligand binding affinity between these t\vo ERs may contribute to the 
selective action of ER agonists and antagonists in different tissues (Kuiper et al.. 1997). 
The phytoestrogens will compete with the natural estrogens for estrogen receptors but 
may be limited to the binding stages and fail to transmit the hormonal message to RNA. The 
ability of some phytoestrogens to send messages to nuclei once they are bound to the uterine 
receptors has been studied by Tang and Adams (1980). They observed that equol can bind to 
estrogen receptors as does estradiol, but the rate of synthesis of DNA and protein by rat 
uterus was 80% higher in the rats receiving estradiol (5 (j.g subcutaneously) than that by rats 
receiving equol (5 mg subcutaneously). These data showed that, although phytoestrogens 
can bind to estrogen receptors in different tissues, their cellular responses were different from 
when natural estrogens were used. 
Daily intake of 60 grams of soy protein containing 45 mg of soy isoflavones for one 
month significantly increased follicular phase length and delayed menstruation in six 
premenopausal women with regular menstrual cycles. This effect was similar to that caused 
by the antiestrogen tamoxifen (Cassidy et aL 1994). Lu at al. (1996) fed soymilk to healthy 
females 22 to 29-year-old for one month on a metabolic unit. The daily intake of daidzein 
and genistein was 100 mg each. Serum 17 P-estradiol levels on menstrual cycle days 5-7, 
12-14, and 20-22 decreased by 31%, 81% and 49% respectively, during soymilk feeding. 
Decreases persisted for tvvo or three menstrual cycles after withdrawal for soymilk feeding. 
Menstrual cycles were increased from 28 days to 32 days, remained at 32 days at one cycle 
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after termination of soy feeding and returned to pre-soy diets length five to six cycles later. 
They concluded that consumption of soy foods containing isoflavones might reduce 
circulating ovarian steroids and adrenal androgens and increase menstrual cycle lengths. 
Isoflavones can stimulate sex hormone binding globulin (SHBG) synthesis in the 
liver, in this way, they may reduce the biological effects of sex hormones (Adlercreutz et al., 
1987). SHBG binds estrogens to provide a circulating reservoir of estrogen. .Aji increase in 
SHBG decreases the relative amount of free estrogens, thus decreases the metabolic 
clearance rate of estrogen and reduces estrogen uptake and action in peripheral tissues, 
thereby lower their biological activity. Adlercreutz et al. (1987) showed the positive 
correlation between the excretion of total phytoestrogen metabolites with plasma SHBG 
levels and negative correlation between total phytoestrogen metabolites with percentage free 
estradiol in plasma. In vitro studies using HepG2 liver cancer cells demonstrated that 
genistein and daidzein stimulate SHBG synthesis (Mousave and Adlercreutz 1993). 
The activity of aromatase, the rate-limiting enzyme in estrogen synthesis, is inhibited 
by isoflavonoids and lignans (Campbell and Kurzer 1993; Wang et al., 1994). Lignans are a 
group of diphenolic compounds with molecular weight similar to those of steroid estrogens. 
This inhibitory effect on aromatase may be another mechanism for isoflavones' 
antiestrogenic effects. Enterloactone, the most abundant lignan with mammalian activity, is 
a moderate inhibitor of placental aromatase and competes with the natural substrate 
androstenedione for binding to the enzyme (Adlercreutz et al., 1993). 
Numerous evidences support both estrogenic and antiestrogenic activity of 
isoflavones. Whether isoflavones are estrogenic or antiestrogenic depends upon the 
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concentrations of exogenous isoflavones vs. the levels of endogenous estrogens, as well as 
the sensitivity of target tissues and cells to these compounds. 
F. Isoflavone Metabolism and Bioavailability 
The predominant isoflavones in normal soy products are the glucoside forms of 
daidzein, ganistein and glycitein (Wang and Murphy, 1994). Once ingested by humans, the 
glucoside forms may undergo chemical hydrolysis by gastric acid or enzymatic hydrolysis by 
intestinal microflora (Xu et al., 1995) to yield aglycones. These aglycones can be absorbed 
from the intestinal lumen and undergo phase I and II biotransformation reactions, or they can 
be metabolized and broken down by the gut microflora to different metabolites. Equol. O-
desmethylangolensin (O-dma) and dihydrodaidzein have been identified as the major 
metabolites of daidzein in sheep as well as in humans (Kelly et al., 1993). Genistein can be 
metabolized to dihydrogenistein. or p-ethylphenol in sheep (Shutt. 1976) (Figure 6). 
However, no metabolites have been identified for glycitein to date. The glucosides of 
isoflavones are very poorly absorbed in the small intestine compared with their aglycones 
because they have relatively higher molecular weight and hydrophilicity (Brown, 1988). 
Bioavailability refers to the proportion of certain substance absorbed and enters the 
systemic circulation. The metabolism of ingested isoflavones varies greatly in human 
subjects feeding soy products (Xu et al., 1995; Cassidy et al., 1994; Kelly et al., 1993). The 
bioavailability of daidzein and genistein was investigated by Xu et al (1995) by feeding 
human subjects soymilk as the isoflavone source. The average 24-h urinary recoveries of 
daidzein and genistein were approximately 21% and 9%, respectively. Total fecal excretion 
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Figure 6. Metabolisms of daidzein and genistein in sheep. 
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of isoflavones was only 1-2% of the ingested amount. Urinary recovery of daidzein was 
significantly greater than that of genistein and daidzein is thought to be more bioavailable 
than genistein. The lower molecular weight and greater water solubility of daidzein 
compared with genistein might be one of the reason that daidzein is more readily excreted in 
urine than is genistein (Xu et al., 1995). Significant bacterial degradation of isoflavones 
might explain the relative low recoveries of daidzein and genistein in urine and feces. 
Twenty-four hrs after dosing, the concentrations of daidzein and genistein in both plasma and 
urine were only at trace levels, which demonstrated the rapid metabolism of daidzein and 
genistein once ingested. The bioavailability of glycitein was compared with daidzein and 
genistein by feeding 4.5 umole/kg total isoflavones from soymilk and soygerm to 7 females 
and 7 males (Zhang et aL 1998). Average 48 hrs urinary recoveries of glycitein. daidzein 
and genistein were approximately 55%. 46% and 29%, which suggested that glycitein is 
more bioavailable than daidzein and genistein. 
Isoflavones undergo urinary as well as biliary excretion in rats (Axelson and Setchell, 
1981) and humans (Rondelli et uL, 1991). The intestinal uptake, biliary excretion of 
genistein was investigated in rats by using 4-''' C-genistein (Sfakianos et al., 1997). 4-'"' C-
genistein, when infused into the duodenum, was rapidly absorbed from the intestine, taken up 
by the liver and excreted into the bile as 7-0-P-gluciu"onide conjugate. The total recovery of 
C-radioactivity over the next four hours in bile was 70 -80% of the administered dose. 
When rats were placed in metabolic cages, and urine and feces were collected for 120 h after 
dosing, the total C-genistein excreted in urine and feces was 21% and 2%, respectively. 
Sfakianos et al (1997) demonstrated that genistein undergoes an efficient enterohepatic 
circulation. As a result, genistein may accumulate within the enterohepatic circuit and may 
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be excreted with a long half-life. They suggested that the measurement of urinary genistein 
during the first 48 h after administration of genistein by most researchers might 
underestimate genistein's bioavailability. 
King et al (1998) investigated the plasma and urinary kinetics of daidzein and 
genistein in humans by feeding them a single soy meal. Isoflavone concentrations in plasma 
rose slowly and reached maximum values of 3.14 |j.M at 7.42 h for daidzein and 4.09 jiM at 
8.42 h for genistein. The rate of urinary excretion of daidzein was greater than that of 
genistein throughout of the postmeal period, with mean recoveries of 62% and 22% for 
daidzein and genistein, respectively. However, the ratio of the areas under the plasma 
concentration versus time curves for daidzein and genistein was equal to the ratio of the 
concentrations of the respective isoflavones in the soy meal. They concluded that the 
bioavailability of daidzein and genistein are similar, even though daidzein had higher urinary 
excretion. 
The absorption and excretion of the soy isoflavone genistein and daidzein have been 
investigated by King et al (1996) in rats given a single oral dose of genistein (20 mg/kg body 
weight) or an equivalent dose of its glucoside forms, as an isoflavone-rich soy e.xtract. 
Plasma concentration at 2 h after dosing was approximately 11 |J.M in genistein-treated rats 
compared with 5 |iM in soy extract-treated rats, but there were no differences after 8 hrs. 
This suggests that the extent of absorption of genistein is similar for genistein and its 
glucoside forms. The fecal excretion of genistein and daidzein over the 48 h post-dosing 
collection period was 22% and 6% respectively. The large difference between fecal 
excretion of genistein and daidzein may reflect the greater bioavailability of daidzein 
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compared with genistein. The isoflavone concentrations achieved in rats were comparable to 
that in humans (Xu et al 1995; King et al 1998). 
In vitro anaerobic incubation of daidzein and genistein with human feces showed that 
daidzein completely disappeared after 72 h and genistein after 18 h. The loss of isoflavones 
seemed to follow first-order kinetics, with the half-life of daidzein and genistein estimated at 
7.5 and 3.3 h, respectively (Xu et al.. 1995). Human intestinal bacteria can metabolize and 
degrade isoflavones as well as liberate isoflavone aglycones. The bacteria in the 
gastrointestinal tract play an important role in determining the magnitude and pattern of 
isoflavone bioavailability (Xu et al., 1995). The extensive metabolism and degradation of 
isoflavones by intestinal microflora prohibit their resorption fi"om lower bowel and this might 
explain the strong association between high fecal isoflavones and greater total urinary 
recovery of isoflavones. Also the shorter half-life of genistein than daidzein might help to 
explain why less genistein could be absorbed than daidzein. In humans, the concentrations of 
e.xcreted metabolites can vary many orders of magnitude from individual to individual (Kelly 
et al., 1993; Xu et al., 1995), and likely the resuU of different human gut bacteria. 
G. Are Isoflavones Cancer Preventive? 
Epidemiological studies report that the consumption of soy is associated with a lower 
risk of breast, colon and prostate cancer (Lee et al., 1991; Messina et al., 1994; Barnes et al., 
1994; Parker et al., 1996). The prevalence of breast cancer is much higher in Western 
countries than in Asian countries. Age-adjusted death rates from breast cancer range from 20 
to 26 deaths per 100,000 for Northern Europe and North America, but are only 4.9 and 6.6 
deaths per 100,000 in China and Japan (Parker et al., 1996). Western diets usually do not 
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contain soy products, as a result, they are almost completely lacking in isoflavones. In 
contrast, Asian diets contain substantial amount of soy products, which are rich sources of 
isoflavones. Urinary isoflavone excretion was 20-30 times greater among Japanese women 
and men consuming typical traditional diets compared with the values from women in the 
United States, and this urinary isoflavone excretion is the result of soy product consumption 
(Adlercreutz et al.. 1991). In a case-control study, Ingram et at. (1997) showed that 
increased excretion of isoflavones is associated with a substantial reduction (30%) in breast 
cancer risk. 
The antioxidant, estrogenic and antiestrogenic activities all have been postulated as 
mechanisms for soy isoflavones' ability to lower cancer risks. In addition, isotlavones have 
other interesting biological activities, which may be critical in their health-enhancing 
properties. Genistein has been shown to be a specific inhibitor of tyrosine-specific protein 
kinases (Akiyama et al., 1986). Tyrosine kinase phosphorylates tyrosine residues on proteins 
involved in signal transduction events in both normal and tumor cells. Tyrosine-specific 
protein kinase activity is known to be associated with oncogene products of the retroviral src 
gene family. This activity is also associated with the cellular receptors for several growth 
factors such as epidermal growth factor, platelet-derived growth factor, insulin and insulin­
like growth factor (Akiyama et al., 1986). Thus, a tyrosine kinase inhibitor like genistein 
could be an antitumor agent. Genistein is capable of inhibiting the growth of a wide range of 
both human and rodent cancer cell lines with IC50 values ranging firom 5 to 40 |j.M (Messina 
et al.., 1994). Genistein has also been shown to inhibit the activity of DNA topoisomerases 
(Okura et al., 1988). Topoisomerases alter the linking number of DNA by catalyzing the 
cleavage of one or both strands of the DNA, passage of a segment of DNA through this 
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break, then releasing the DNA break. Topoisomerases are very important in the process of 
replication, transcription and other DNA processes. 
By using noncytotoxic concentrations of agents that promote terminal differentiation 
of human tumor ceils is one of the major strategies in fighting cancer. Genistein has been 
shown to be an inducer of human HL-60 tumor cell differentiation in a dose-dependent 
manner (Constantinou and Huberman, 1995). Genistein has been shown to have the ability 
to induce in vitro differentiation of mouse erythroleukemia cells at low concentrations of 
about 20 |j,M (Watanabe et al., 1991). Makishima et al. (1991) reported that genistein has 
the ability to induce human ML-1, HL-60 and U937 leukemia cells to undergo granulocytic 
differentiation. 
Soybean isoflavone extract, with total normalized isoflavone 1 mmol or 2 mmol/lcg 
diet, suppressed hepatocarcinogenesis in female Fisher 344/N rats as evidenced by the 
decreased volume percentage of gamma-glutamyltransferase (GGT)- and placental glutathine 
S-transferase (PGST)-positive altered hepatic foci (AHF) after 3 months of feeding, which 
were initiated by diethylnitrosamine (15 mg/lcg body wt) and promoted by phenobarbital 
(500 mg/kg diet) (Lee et al., 1995). 
Barnes et al. (1990) showed that rats consuming a soy-based diet develop fewer 
mammary tumors following the administration of carcinogen N-methylnitosourea and 7.12-
dimethylbenz-anthracene than rats on isocaloric diets widiout soy. They claimed that the 
hypothesis about Bowman-Birk inhibitors as anticarcinogens (Troil et al., 1984) are incorrect 
because they did not observed different effects of autoclaved soy and non-autoclaved soy in 
suppressing cancer development. However, Bowman-Birk inhibitors in soy have very 
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unique structure and could not be destroyed by normal autoclave treatment. The possibility 
of Bowman-Birk inhibitor in soy as anticarcinogen is still under investigation. 
Genistein has been shown to alter the ontogeny of mammary gland development and 
protect against chemically induced mammary cancer in rats. The mechanism of this 
chemoprevention is probably via alteration of early mammary gland maturation 
(Lamartiniere et al., 1998). In this study, female Sprague-Dawley CD rats were treated via 
subcutaneous injection on day 2, 4. and 6 postpartum (neonatally) with 5 mg genistein/rat or 
equivalent volume of the vehicle, dimethylsulfoxide (DMSO). In the second study, female 
rats were injected on day 16. 18 and 20 postpartum (prepubertally) with 0.5 mg genistein/g 
body weight or an equivalent volume of DMSO. .Animals treated with genistein developed a 
lower incidence of dimethylbenzanthracene (DMBA)-induced mammary tumors compared to 
the control group. The numbers of tumors/animal were reduced by approximately 50% in 
both studies. Rats exposed neonatally to genistein, but not prepubertally to genistein. had 
significantly increased mean time to tumor detection compared to vehicle-treated animals. 
Neonatal and prepubertal genistein treatments resulted in increased mammary gland sizes in 
21- to 22-day-old female rats compared to vehicle-treated rats. 
•Angiogenesis refers to new blood vessel growth, and the formation of new blood 
vessels is critical for the growth of tumor. Genistein was shown to inhibit in vitro 
angiogenesis (Fotsis et ai. 1995). Bovine microvascular endothelial (BME) cells seeded on 
the surface of collagen gels invade the gels when exposed to basic fibroblast growth factor 
(BFGF) and form capillary like tubes beneath the gel surface. Genistein at 200 |j.M, when 
added together BFGF, inhibited BME culture's ability to invade the gels and generate 
capillary like structures. Genistein inhibited BFGF-induced invasion of BME cells with a 
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half-maximal effect at approximately 150 |aM concentration. However this concentration is 
way above the physiological feasible genistein concentration, and whether or not this 
inhibitory effect of genistein on angiogenesis may help to suppress the growth of cancer cells 
through anti-angiogenesis needs further investigation. 
Several studies have looked at the effects of soy isoflavone intake on experimental 
liver cancer or markers of liver cancer. Daidzein and genistein at I mmole/kg diet 
suppressed 35 umol/lcg diet flimonisin B1 (FBl)-promoted rat hepatocarcinogenesis. but 
showed little or no effects on a 70 umol/kg diet of FBI (Lu et al.. 1998). Mokhtar et al. 
(1988) reported that in rats administered dibutylamine and nitrite, the severity of liver 
dysplasia was reduced and liver tumors were inhibited in soy-based diet fed animals 
compared with control which have no soy in the diet. 
Soy isoflavones have been evaluated regarding their ability to suppress skin cancer. 
In a mouse skin tumor model, the dimethyl sulfoxide extracts of soybean hypocotyls 
(hypocotyls have higher concentration of isoflavones than whole soybeans) were shown to 
have strong inhibitory' effect on tumor formation (Zaizen et al.. 1997). In the same study, the 
extract as well as daidzein have been shown to have inhibitory effect on Epstein-Barr virus 
early antigen activation induced by 12-0-tetradecanoylphorbol-l3-acetate. 
Isoflavones have been shown to stimulate natural killer (NK) cells activity (Zhang 
1997), and this may be another mechanism for their anticarcinogenic effects because NK 
cells represent a subset of lymphocyte with the ability to spontaneously kill tumor or virus-
infected cells. NK cells play essential roles in immune surveillance against tumors and 
infectious agents and the activity of NK cells has been correlated with the ability to fight 
tumors. .A decrease in NK activity has been found to be associated with the development and 
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progression of cancer (Whiteside and Herberman, 1989). Soy isoflavone extracts can 
significantly increase NK cell activity in rats. .A^fter rats were fed 240-mg isoflavones/kg diet 
for 10 days. liver associated NX cell activity was two fold higher than that in the control 
group (Cunnick and Hendrich, unpublished data). The effect of daidzein on immune 
function in mice was investigated by Zhang et al (1997). Swiss mice were fed daidzein at 
various doses for 7 days. .A.t high doses 20 and 40 mg/lcg body weight, daidzein exerted a 
stimulatory effect on nonspecific immunity. The phagocytic response of peritoneal 
macrophages and thymus weight was increased in a dose-dependent manner. .Activation of 
humoral and cell-mediated immimity was observed. 
Adlercreutz (1998) has summarized the possible mechanisms of isoflavone and other 
phytoestrogen's anticancer effects: (1) Inhibition of tyrosine and other kinases: 
(2) Stimulation of production of sex hormone binding globulin; (3) Estrogenic and 
antiestrogenic activity, binding to estrogen nuclear type-II binding sites: (4) Inhibition of 
angiogenesis and tumor invasion; (5) .Antioxidant activity; (6) Prolongation of menstrual 
cycle; (7) Inhibition of proliferation and stimulation of differentiation of tumor cells; (8) 
Inhibition of steroid enzymes, e.g. .Aromatase. 17p-hydroxysteroid dehydrogenases; (9) 
Decrease of sensitivity of breast cells to toxic compounds before puberty. .A.lthough no firm 
conclusions can be reached at this time, the correlation between isoflavone consumption and 
lower risk of certain types of cancer is clear and the mechanisms of the observed anticancer 
effects are still under investigation. 
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H. Soy Protein Is Hypocholesterolemic; What About Soy Isoflavones? 
The cholesterol-lowering effects of soy protein as compared with animal protein 
(casein) consumption have been recognized in animals for more than 80 years. Carroll 
(1991) reviewed the evidence of the hypocholesterolemic effect of soy protein. Numerous 
studies conducted by different researchers have found that adding soy protein to the diet, or 
replacing casein with soy protein, lower plasma cholesterol levels in animals as well as in 
humans. Hamsters, rats, mice, rabbit and monkeys are the models that have been used to 
evaluate the hypocholesterolemic effects of soy protein. Monkeys have similar cholesterol 
profiles and metabolisms as humans, however, because they are expensive to obtain and 
maintain, not many studies have been performed on monkeys. The rat. in spite of marked 
differences in cholesterol profile and metabolism from human, has provided important 
information about cholesterol and lipoprotein metabolism. Spady and Dietschy (1983) 
observed that some aspects of cholesterol metabolism in hamster are quite similar to those 
observed in humans. More recently, hamsters were used as models to study cholesterol and 
lipoprotein metabolism. The rabbit is a species very susceptible to diet-induced 
hypercholesterolemia and has been widely used in cholesterol smdy (Carroll et al 1975; 
Terpstra et al 1983). 
Sirtori et al. (1985) reported that substitution of soy protein for animal protein in the 
diet of very hypercholesterolemic human subjects led to a marked 20 to 30% reduction in 
serum total and LDL cholesterol levels. The intake of 25 g of soy protein, with or without 
soybean fiber, significantly lowered total cholesterol levels in men with elevated plasma 
cholesterol concentrations (Bakhit et al. 1994). However, in most of the human studies, the 
number of participants was limited and the results lacked statistical power. Anderson et al. 
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(1995) conducted a meta-analysis, which combined 29 studies using human subjects. They 
found that in most of the studies, the intake of energy, fat, saturated fat and cholesterol was 
similar for the subjects ingesting control and soy-containing diets and the average intake of 
soy protein was 47g/day. The ingestion of soy protein compared with casein was associated 
with the following changes in plasma lipid levels: (1) a 9.3% decrease in total cholesterol 
levels (P<0.05); (2) a 12.9% decrease in LDL cholesterol levels (P<0.05); (3) a 10.5% drop 
in triglyceride levels (P<0.05); (4) the changes in total and LDL cholesterol levels were 
directly related to initial serum cholesterol concentrations (P<0.01); and (5) HDL cholesterol 
levels were not significantly different from control with a 2.4% increase. 
The mechanisms for the hypocholesterolemic effects of soy protein consumption in 
animals and humans are not known. There are several different factors in soy proteins that 
may be responsible to the hypocholesterolemic effect. Carroll et al. (1995) suggested that the 
active hypocholesterolemic component in soy may be the amino acid pattem and peptide 
structiu^e of soy protein. Setchell et al. (1984) suggest that soy estrogens may contribute to 
the cholesterol-lowering effects of soy protein. Manzoni et al. (1998) suggested that the 
ability of different soy globulins to up-regulate hepatic LDL uptake and clearance might play 
critical role in soy protein's hypocholesterolemic effects. In their study, the LDL receptor 
activation has been observed in a human hepatoma cell line (Hep G2) e.xposed to the 7S 
globulin from soy. In addition, soy saponins and dietary fibers in soy have been proposed to 
have the ability to lowering plasma cholesterol levels (Potter, 1995). 
The first evidence linked isoflavones to hypocholesterolemic effects was provided by 
Siddiqui (1975) where they reported that crude biochanin A and formononetin extract, when 
added to casein-based high fat and cholesterol-enriched diet at 1.5 g/kg diet, significantly 
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lowered the serum cholesterol level (35%) when compared with the group with no 
isoflavones in albino rats. 
Anthony et al (1995) reported that, in male and female peripubertal rhesus monkeys, 
soy protein with intact isoflavones (1.27 mg genistein and 0.47 mg daidzein per gram of 
protein, 200 g protein/kg diet) significantly lowered plasma total and LDL-cholesterol levels 
compared with isoflavone depleted soy protein where 90% of the isoflavones were removed. 
Balmir et al. (1996) reported that an ethanol and acetone extract of soy flour, which 
contains 60% isoflavones, when added to casein diets (40, 90 mg total isoflavones/lcg diet), 
significantly reduced the plasma cholesterol levels in both rats and hamsters. Soy proteins, 
with or without isoflavones, both decreased serum cholesterol levels compared with casein 
control group. However, there were no differences between these two different soy protein 
groups. 
Tovar-Palacio et al. (1997) reported that soy protein lowered plasma cholesterol 
levels in the gerbil. But when isoflavones concentrates were added to the soy protein groups 
at three different doses of 2.1. 3.6 or 6.2 mg isoflavones / g protein, they did not reduce 
cholesterol levels further than soy protein alone. However, these diets did reduce cholesterol 
levels significantly compared with casein control groups. 
All these studies provide indirect evidence that isoflavones may be the factors that 
contribute to soy's hypocholesterolemic effects. However, because all the isoflavone 
extracts used in the experiments contain other compounds from soy, such as soy saponins 
and phenolic acids, the role of isoflavones on serum cholesterol levels is not resolved at this 
time. However, the studies by Balmir et al (1996) did prove that soy protein without 
isoflavones retains its ability to lower serum cholesterol levels. 
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Studies in rats have shown that soy protein compared with casein increase fecal 
excretion of bile acids (Nagata et al., 1982). Hepatic cholesterol metabolism then shifts to 
provide cholesterol for enhanced bile acid synthesis. As a result, increasing amoimt of 
cholesterol will be removed from blood via the apo B/E receptor and the serum cholesterol 
levels decrease (Beynen, 1990). Other possible mechanisms include (1) increased thyroid 
hormone levels (Balmir et ai., 1996), so that the lipolysis and fatty acid utilization might be 
stimulated; (2) suppression of lipogenic enzyme gene expression (Iritani et al., 1995), as 
results, the synthesis of fatty acids is suppressed; or (3) increased LDL receptor activity 
(Lovati et al. 1998). Baum et al (1998) reported that levels of mRNA for LDL receptors are 
greater in mononuclear cells from himians fed isolated soy protein compared with milk 
protein. The increased level and activity of LDL receptor will increase the clearance of 
cholesterol from blood and lower serum cholesterol levels would be achieved. The 
correlation between isoflavone intake and lower level of serum cholesterol is getting more 
and more supportive evidence and the mechanisms for isoflavones' effects on cholesterol 
level are to be clarified in the future. 
I. Soy Isoflavones: Cure for Postmenopausal Osteoporosis? 
As the life expectancy continues to rise, osteoporosis is becoming a more important 
aspect of health care costs. Osteoporosis is associated with ovarian hormone deficiency 
following the menopause and is the predominant cause of age-related bone loss (Gruber et 
al., 1984). Estrogen replacement therapy is the most effective method to reduce 
postmenopausal bone loss, but it is accompanied with side effects such as the increased risk 
of endometrial cancer (Genant et al., 1989). Reports have indicated that ipriflavone (7-
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isopropylisoflavone), a synthetic isoflavonoid derivative, is very effective in preventing bone 
loss in experimental osteoporosis (Benvenuti et al., 1991; Yamazaki, 1986). At dose of 600 
mg/day, ipriflavone prevented both postmenopausal and senile osteoporosis (Agnusdei et al.. 
1992; Nakamura et al.. 1992). Interestingly, one of ipriflavone's metabolites is daidzein 
(Brandi, 1993). Because of isoflavone's estrogenic activity, they might be effective in 
preventing bone loss caused by estrogen deficiency. 
•Ajjmandi et al (1996) tested the ability of soy protein isolate to prevent bone loss in 
an ovariectomized rat model of osteoporosis. The soy protein (227 g/kg diet) as well as 17 P-
estradiol (10 |ag/kg body weight/day) gave significantly higher bone density in 
ovariectomized rats compared to the ovariectomized rats receiving diets without soy or 
estradiol. The biochemical markers of bone turnover, alkaline phosphatase and tertrate-
resistant acid phosphatase, were significantly lower in soy group than control. They 
concluded that soy protein is effective in preventing bone loss due to ovarian hormone 
deficiency and suggested that the isoflavones in soy protein may be the major factors. In a 
recent study. Blair et al. (1996) have shown that genistein administered in the diet can 
significantly increase the mass of weight bearing bones compared to control in 
ovariectomized rats. Draper et al (1997) reported that coumestrol, zearalanol reduced bone 
loss and bone resorption in ovariectomized rats, a model of postmenopausal bone loss. 
Ishida et al (1998) reported that daidzin and genistin, at doses of 50 mg/kg body weight/day, 
both prevented the bone loss in ovariectomized rats fed a calcium-deficient diet. 
The ovariectomized, lactating rat model has been used to investigate the skeletal 
effects of genistein over a 14-day period (Anderson et al., 1998). Three doses, 
05.mg/rat/day, 1.6 mg/rat/day and 5 mg/rat/day, were given to rats following 
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ovariectomization (OVX). A positive control group received premarin, an estrogen. The 
OVX rats receiving no estrogen or genistein (control) on a low-calcium diet loses slightly 
more than 50% of its bone mineral mass during the first two week of lactation. However, the 
estrogen and genistein significantly reduced the bone mineral mass loss compared to the 
control rats. Genistein may act through osteoblastic cells to inhibit osteoclastic bone 
resorption and the effects may be mediated by binding to estrogen receptors or by altering 
cellular activity of tyrosine kinase. Genistein may both stimulate the maturation of osteoblast 
precursors and act on mature osteoblasts to increase the secretion of cytokines, cytokines 
may iirhibit osteoclastic activity and thus reduce bone resorption (Anderson et al.. 1998). 
J. Isoflavones and Alcohol Intake 
Kudzu {Pueraria lobata) is one of the earliest medicinal plants used in traditional 
Chinese medicine as antidipsotropic (antialcohol abuse) agents (Keung and Vellee. 1998). 
Interestingly, daidzein was found at 950 |ig/g in kudzu (Kaufman et al., 1997). Keung et al 
(1993) reported that daidzin is a potent, reversible and selective inhibitor of human 
mitochondrial aldehyde dehydrogenase (ALDH). At low concentration of 0.1 (iM, daidzin 
appeared to inhibit human ALDH competitively with respect to acetaldehyde. In 1997, they 
reported that an i.p. dose of daidzin or daidzein (70 meq per hamster per day) suppressed the 
alcohol intake by 32% and 62% respectively of Syrian golden hamsters. There is a direct 
relationship between ALDH activity and the body's ability to metabolism aJcohol, by 
inhibiting ALDH activity, the appetite of alcohol intake may be suppressed. 
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SOY ISOFLAVONE ANALYSIS: QUALITY CONTROL AND NEW 
INTERNAL STANDARD 
A paper accepted by the American Journal of Clinical Nutrition 
Tongtong Song'. Kobita Barua". Gwen Buseman', and Patricia A Murphy' 
Abstract 
Development of a database for soy isoflavone in foods requires accurate and precise 
evaluation of different food matrices. To evaluate accuracy, we estimated recoveries of both 
internal and external standards in 5 different soy foods weekly. Standards are evaluated daily 
for system quality assurance. To evaluate sample precision, we analyzed soybeans and 
soymilk for within-day precision and over 4 days for day-to-day precision bimonthly. 
Coefficients of variation (cv) should be < 8 %. We have validated our methods for single and 
multiple recovery levels using our new internal standard, 2,4,4'-trihydroxydeoxybenzoin 
(THB), and external standards, daidzein, genistein and genistin. Levels of 12 isoflavone 
isomers, three aglycones ( daidzein, genistein, glycitein) and nine glucosides (daidzin, 
genistin, glycitin; acetyl-daidzin, -genistin,-glycitin; malonyl-daidzin, -genistin, -glycitin) 
have been measured in a variety of soybeans and soy foods. Extraction methods vary 
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dqjending on soy food type. The HPLC conditions for soy isoflavone analysis has been 
improved, leading to a good separation with a short analysis time- 60 minutes per sample. A 
data bank of concentration and distribution of isoflavones in different soybean products was 
assembled by HPLC analysis. A wide range of isoflavone concentrations, from < 50 |ig/g to 
> 20.000 fag/g, was found in different soy products. The glucoside forms are almost 2X the 
molecular weight of the aglycones, the reported isoflavone levels should be normalized to the 
aglycone mass (or an isoflavanoid equivalent) rather than a simple sum of all isomers. 
KEYWORDS: quality control, internal standard, 2.4,4'-trihydroxydeoxybenzoin (THB). 
HPLC assay, soy isoflavone. 
Introduction 
Dietary intake of soy has been associated with lower incidence of hormonally-
dependent and -independent cancer (1). Soy foods have been associated with lower risk of 
cardiovascular disease (2). Isoflavones may directly inhibit bone resorption (3). In animal 
studies, isoflavones demonstrated anti-cancer capabilities and inhibited the growth of human 
breast and prostatic cancer cells in culture (4). Recent studies have proposed that isoflavones 
may be the factor responsible for the cholesterol lowering property (5) of some soy foods. 
To evaluate the potential of the isoflavones as a dietary health-enhancing compound, the 
amounts available in typical soy foods and in soybeans must be quantified. Soybeans contain 
high amounts of the isoflavones (1-3 mg/g), daidzein, genistein and glycitein ( 6 ). High 
performance liquid chromatography (HPLC) has already been shown to be a powerful 
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method to analyze the isoflavones. Most previous studies of soy isoflavones have focused 
on daidzein and genistein with little attention to glycitein. Glycitein accounts for about 5-
10% of the total isoflavones in soy foods and may have some unique biological activities. 
We are assembling a data bank of the concentrations of 12 isoflavone isomers, three 
aglycones ( daidzein (Dein); genistein (Gein); glycitein (Glei)) and nine glucosides (daidzin 
(Din); genistin (Gin); glycitin (Glin); acetyl-daidzin (ADin); acetyl-genistin (AGin); acetyl-
glycitin (Aglin); malonyl-daidzin (MDin); malonyl-genistin (MGin); and malonyl-glycitin 
(MGlin) ) in soy foods (Figure 1 ). The distribution of different forms of isoflavones 
represents a history of the processing of these foods. Heat processing, enzymatic hydrolysis, 
and fermentation can significantly alter the isomer distribution of the three isoflavones ( 7 ). 
For example, the amount of the malonyl forms, which are very heat sensitive, will be quite 
different between raw and heat-treated soybeans. 
Materials and Methods 
Apparatus. Samples were analyzed on a Beckman System Gold chromatography 
with an autosampler .Model 507, a dual pump Model 126 . a photodiode array detector (PDA) 
.Model 168 and an IBM 486 computer with Beckman Gold system HPLC data processing 
software(version 8 . 1993). All HPLC units are from Beckman Instruments, Fullerton. CA. 
Materials. Chemicals used in the synthesis of THB are resocinol. 4-
hydroxyphenylacetic acid , boron trifluoride etherate (BFjEt^O), N,N-Dimethyl formamide ( 
DMF ) and methanesulfonyl chloride, all purchased fi"om Sigma Chemical Co. (St. Louis, 
MO). Milli-Q system (Millipore Co., Bedford, MA) HPLC grade water was used. HPLC-
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grade acetonitrile {ACN) and methanol used in HPLC analysis were purchased from Fisher 
Scientific (Fair Lawn. NJ). All the soy ingredients and processed soybean products reported 
here were purchased locally, except soygerm, which was generously provided by Schouten 
Industries. Inc.(Minneapolis, MN). 
Synthesis of 2,4,4'-trihydroxydeoxybenzoin (THB) (8). Resorcinol (2.9 g) was 
added to a mixture containing 4-hydroxyphenylacetic acid (2g) and boron trifluoride etherate 
(4.5 mL). The mixture was refluxed for 10 min.. cooled and treated with 30 mL saturated 
NaOAc and 15 mL NaHCO, respectively. The yellow precipitate was filtered and washed 
with water, then washed with CHC1„ dried and give yellow crystals. Redissolved crystals 
were chromatographed through Sephadex LH-20 (Pharmacia LKB Biotech. Inc.. Piscataway. 
NJ) column with 50% ethanol as the mobile phase. A single peak was collected giving high 
purity THB (>99%) for use as internal standard. 
Isoflavone standards. Seven isoflavone standards were used in calibration curves 
including Dein, Gein. Glei. Din. Gin. Glin. AGin (Table 1). Gein was synthesized in this 
laboratory according to Chang et al ( 8 ). Dein was synthesized in this laboratory with 
modification of Chang's method: BFjEt^O (4 mL) was added to a beaker containing 200 mg 
THB in 10 mL DMF. the reaction mixture was heated in microwave oven ( Kerunore U88 ) 
for 30 s using medium energy, then 4 mL of methanesulfonyl chloride was added to the 
mixture. The mixture was heated again in microwave for 70 s using medium energy. Four 
hundred mL of cold water was added to the reaction mixture, giving a light yellow 
precipitate. The precipitate was washed with water and recrystallized from methanol. Gin, 
Din and AGin were available from previous work in this laboratory (6 ). Glin was purified 
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according to Farmakaiidis and Murphy ( 9 ). Glei was purified from soy germ by using the 
following method. Soygerm was hydrolyzed in 0.1 N HCl at 98°C for 2 hour, extracted with 
ACN and filtered through No.42 filter paper. The filtrate was dried by using a rotary 
evaporator at 50°C. The residue was dissolved in 100% ethanol and applied to a Sephadex 
LH-20 column with 50% ethanol as the eluent. The glycitein peak was collected and freeze-
dried. The identification and purity of glycitein was confirmed by HPLC retention time, UV 
spectral analysis, melting point and mass spectnmi. 
Calibration curves and calculation of food levels. Isoflavone stock solutions were 
prepared by dissolving pure standards in 80% methanol to give a concentration around 400 
ug/mL. An aliquot of the solution was then diluted for an absorbance in the range of 0.6 -
0.8. The concentrations of the stock solutions were calculated by absorbance at the 
wavelength vvith maximum absorption using molar extinction coefficients (e) ( 10 ). 
Purity of the standards was calculated based on the percentage of the peak area in the HPLC 
chromatograph. The final stock concentration of each individual standard was adjusted for 
the purity of the standards. 
Standard curves were obtained for most isofiavones with high linearity (r > 0.995) by 
plotting the standard concentration as a function of peak area obtained from HPLC analysis 
of 20 (iL injections. The concentrations of standard solutions were carefully chosen in order 
to cover the possible isoflavone contents based on the previous work in our lab. For the 
isoflavones without a pure standard { MGin, MDin, MGlin, ADin, AGlin), we adjusted the 
standard curves based on the molecular weight differences. 
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We used standard curves to calculate the concentrations of isoflavones in food items. 
The results were expressed as jig isoflavone / g food with consideration for recoveries. 
Isoflavone extraction and HPLC assay. All samples were freeze-dried except for 
the dry soy ingredients and the instant soy beverage. Two grams of dried, finely ground 
sample was placed in a 125-mL screw top Erlenmeyer flask and 10 mL of ACN , 2 mL of 
O.IN HCl ( 6 ) and 5 mL of water were added and stirred for two hours at room temperature. 
Extracts were filtered through Whatman No. 42 filter paper. The filtrate was taken to dryness 
on a rotatory evaporator (BUchi, Brinkmann, Westbury, NY) at < 30*^0. The residue was 
dissolved in 10 mL 80% HPLC-grade methanol in water. A aliquot of sample was filtered 
through a 0.45-|am PTFE filter unit (poly-tetrafluoroethylene) (Alltech. Associates inc., 
Deerfield, IL) and analyzed by HPLC. A YMC-pack ODS-AM-303 column (5|j.m. 25 cm x 
4.6 mm ) was used. A linear HPLC gradient was composed of (A) 0.1% glacial acetic acid in 
water and (B) 0.1% glacial acetic acid in ACN. The chromatography method ( 6 ) has been 
modified with 33% less analysis time for each sample. Following injection of 20 |j.l of 
sample, solvent B was maintained at 15% for 5 min, then increased to 29% in 31 min, after 
that increased to 35% in 8 min and returned to 15% at the end of 45 min. The solvent flow 
rate was I mL/min at the first 5 min, then increased to 1.5 mL/min in 0.5 min and maintained 
for 39 min, then retumed to I mL/min. A Beckman model 168 photodiode array detector 
monitored absorbance fi-om 200 to 350 nm. UV spectra were recorded and peak areas were 
integrated by Beckman Gold system software (version 8, 1993). 
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Recovery study using internal and external standards. Two hundred |iL of 
intemai standard THB (400 |ig/mL in methanol) and different amounts (from 50 fiL to 700 
|j.L dependent upon the sample) of external standards (Gein (1600 |ag/mL), Dein (800 
jag/mL), and Gin (600fag/mL)) in methanol solution were added to 2 g of dry sample. The 
samples were mixed thoroughly, then left at room temperatiu-e until methanol had 
evaporated. The extraction and analysis methods were the same as above. 
Statistical Analysis. All samples were run with two to four replications. Statistical 
analysis including linear regression, average, standard deviation, and coefficients of variation 
(cv) was calculated by using Microsoft Excel 5.0 statistical functions. Analysis of variance 
was done by using the SAS package (Version 5.0) developed by the SAS Institute, Inc. (Box 
8000, Gary, NC ) at a = 0.05. 
Results and Discussion 
Modification of HPLC condition. The HPLC conditions for soy isoflavone analysis 
(6) gave good separation on 12 isoflavone isomers, with a total analysis time of 90 minutes 
for one sample. However, using these HPLC conditions, only 10 to 16 samples could be run 
per day. Therefore, we modified our previous HPLC conditions by programming flow rate 
and mobile phase gradient as described in Methods. We achieved excellent separation of 12 
isoflavone isomers (Figure 2) with a shorter analysis time of 60 minutes. Analysis efficiency 
was improved 50 % where up to 24 samples can be run per day. 
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Modification of isoflavone extraction method. The HCI-ACN extraction procedure 
followed the method described in Murphy (16), which was superior to ail other solvent 
systems in terms of good recovery and less coextractives. During the extraction, the ratio of 
solvent volume versus food material ( mL / gram) was always higher than 6. This method 
worked well for soybeans. In re-evaluating the extracting process, in addition to the HCl and 
ACN, we found that additional water gave better recovery (table 2). For most of the foods, 7 
ml of water was sufficient to maximize extraction. For some unusual samples, different 
amount of water may be used to get the best extraction. Most of the soy products have a total 
isoflavone concentration of 1-3 mg / g. The extraction solvent is, therefore, sufficient for 
removal of the isoflavones. For other soy products, and in particular, isoflavone 
supplements, which havolO mg / g isoflavones. the solvent to sample weight ratio should 
be adjusted. For example, soygerm has very high isoflavone content ( > 10 mg /g) and the 
normal extraction procedure would underestimate the isoflavone content by 10 to 20%. We 
found that an adjustment of the solvent to sample weight ratio to 95 ( 0.2 g sample, 10 mL of 
ACN , 2mL HCl, and 7 mL of water ) resulted in a better extraction of isoflavones. 
THB as a reference peak in soy isoflavone assay. During the HPLC analysis of 
isoflavones, the retention times of the analytes may shift due to several factors, including 
temperature, flow rate and mobile phase makeup. A reference peak in the chromatography 
can aid with peak identification. The computer software in HPLC assay in our laboratory 
measures retention times of analytes relative to the retention time of the reference peak, thus 
avoiding misidentification of analytes due to retention time shifts of peaks. A good reference 
peak should not be found in the sample , it should be stable under the analysis conditions and 
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have a stable retention time and its retention time should be in the range of all the analytes. 
2,4,4'-Trihydroxydeoxybenzoin (THB) is the intermediate for the chemical synthesis of 
daidzein ( 8 ). THB has similar structure and polarity to isoflavones(Figure 1 ). Its retention 
time does not overlap any of the other peaks in our isoflavone chromatogram. It is not found 
in natural foods. It is stable and easy to synthesize. The retention time of THB under the 
HPLC conditions described in Materials and Methods is 36.20 ± 0.40 min. Using these 
HPLC conditions, the 12 soy isoflavone isomers had different retention times (Figure 2 ). 
There is an 'empty* part of the chromatograph (from 32 min to 40 min). THB's retention 
time falls in this range, does not overlap any of the isoflavones. THB was used as the 
reference peak to adjust the retention times of all other analytes. By using a reference peak 
as an anchor, the computer software can assign identification to isoflavone peaks on the basis 
of their retention times relative to THB and calculate their concentrations from standard 
curve data. 
THB as internal standard. There will be certain losses during the multi-step 
extraction of isoflavones, and an internal standard should be required for precise isoflavone 
quantification. An ideal internal standard should be a compound structurally related to the 
analyte with a similar polarity, but with a retention time that does not overlap with other 
peaks in the chromatography. Few isoflavone investigators use internal standards to adjust 
the analyte loss in extraction and analysis (11, 12, 13,14). Most of those compounds that 
have been used as internal standards were either not structurally related to the analytes, or 
have retention times which conflict with the isoflavone peaks. Flavone, used by Franke et al( 
15 ) as an internal standard, eluted much later than the latest eluting isoflavone - Gein. Using 
flavone as internal standard will greatly increase the analysis time for each sample. So for an 
efficient isoflavone analysis, flavone may not be a good internal standard. We tested THB 
as an internal standard. To use an internal standard, known mixtures of standard (THB) and 
analjite are used to construct a standard curve ( Figure 3). When the known amount of 
internal standard is added to an unknown sample, the calibration curve can be used to find the 
concentration of unknown. If a standard is added to a sample prior to extraction, then the 
fi-action of standard lost during the extraction is the same as the fraction of sample lost and 
the ratio of unknown and standard concentration remains the same. We used the internal 
standard curve method to assay the Gin concentration in five different soy samples (textured 
vegetable protein (TVP), tofu, soybean, soymilk and tempeh). The results firom internal 
standard method were compatible to the results from HPLC chromatography without using 
internal standard (The difference is between 3 - 10%). For Dein and Gein, we found that the 
results from intemal standard method were also compatible to the HPLC method, with a 
difference < 10 %. This indicated that our extraction method works well. 
Recovery studies of external standards. Recovery experiments were carried out 
with Dein, Gein, Gin and THB. The recovery results in table 3 show that daidzein, genistein 
and genistin gave different recoveries. This is probably because these isoflavones bind 
differently to the food matrices. The extraction method was designed to optimize the 
extraction of the glucoside forms of isoflavones because, for most soy products, they account 
for more than 90 % of the total isoflavones ( 6 ). This may explain the lower recovery of the 
more hydrophobic free forms (Dein and Gein). 
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Multiple level recovery assay. The use of external standards of isoflavones that are 
already present in the food, is another way to evaluate multiple levels of recovery. As an 
example, we added different known amounts of genistin to tofii. A plot of total genistin 
versus genistin added to the sample yielded a good linear regression line (Figure 4). We can 
use this external standard recovery curve's Y-intercept as the actual amount of Gin in our 
food sample. The same evaluations were done in tofu with Dein or Gein. With Dein we 
obtained a multiple recovery curve of Y=0.996X -i- 178.95, R*=0.9885. With Gein. we 
obtained a curve of Y= 1.0143X 279.67, R"=0.9976. 
PrecisioQ of the analysis. We analyzed two soy foods, Vinton soybeans and freeze-
dried soymilk with different analyte concentrations every month with four replications per 
day to determine the precision of our procedure. Table 4 presents the results from Vinton 
soybeans. The within day cv was 4% and between day cv was less than 8% . We obtained 
within day cv < 5% and between day cv < 10% for soymilk. These samples are good 
representatives of typical soy foods. The small CVs indicated good precision in our 
analytical procedure. 
Food levels. By using methods described in this paper, some representative results of 
soy foods analyzed are presented in Table 5. These foods include soy ingredients (soybeans, 
TVP, soy isolate), traditional soy foods (roasted soybeans, tofu, tempeh, fried tofia, miso), 
second-generation soy foods (soy hot dog) and soy supplement product ( Soygerm). We 
recalculated the results with adjustment for recoveries. For aglycones, we used the average 
recovery of Dein and Gein, 90%. For all the glucoside forms, we used the recovery of Gin, 
97%. Since different lots of soy products than previous report were analyzed by the modified 
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extraction method and reported by adjustment for recovery, there appears to be considerable 
variation in isoflavone levels from lot to lot of same products which was not unexpected. 
The normalized concentrations of each individual isoflavone (daidzein. genistein and 
glycitein) are reported. These values are calculated by multiplying the mass of each 
individual isoflavone form by the ratio of its aglycone molecular weight / molecular weight 
of individual form before summing. For example. Gin amounts would be multiplied by 270 / 
432 to give free Gein represented by Gin. The total isoflavone in each food sample is not the 
simple sum of the mass of the 12 isomers. The isomers will be hydrolyzed to free forms in 
the gut prior to absorption. Thus, normalized results give a pictiu-e of the "effective" 
isoflavone concentration in food. 
Acknowledgements 
This report was supported in part by U.S. Army Medical Branch Breast Cancer Institutive, 
Infr^tructure grant and by the Iowa Agricultute and Home Economics Experiment Station, 
Ames, Iowa, Project 3353 and published as Journal paper. 
78 
References 
1. Messina M.; Barnes S.. The role of soy products in reducing cancer risk. J. Natl. Cancer 
Inst. 1991:83:541 -546. 
2. .Anderson J.W: B.M. Johnstone and M.E. Cook-Newell. Meta-analysis of the effects of 
soy protein intake on serum lipids. N. Engl. J. Med. 1995; 333: 276 - 282. 
3. Bahram H.A., Alekel L.. Hollis B. W.. Amin D.. Stacewicz-Sapuntzakis M.. Guo P. and 
Kukreja S. C. Dietary Soybean Protein Prevent Bone Loss in an Ovariectomized Rat Model 
of Osteoporosis. J Nutri. 1996: 126: 161-167. 
4. Peterson G. and Barnes S. Genistein inhibition of the growth of human breast cancer 
cells : independence from estrogen receptors and the multi-drug resistance gene. Biochem. 
Biophys. Res. Commun. 1991: 179: 661 - 667. 
5. Anthony M.S.: Clarkson T.B.: Hughes C.L.: Morgan T.M. and Burke G.L. Soybean 
isoflavones improve cardiovascular risk factors without affecting the reproductive system of 
peripubertal rhesus monkeys. J Nutri. 1996: 126 ; 43 - 50. 
6. Wang H.J. and Murphy P.A. Isoflavone content in commercial soybean foods. J. .A.gric 
FoodChem. 1994;42:1666-1673. 
7. Wang H.J. and Murphy P.A. Mass balance study of isoflavones during soybean 
processing. J. Agric. Food Chem. 1996; 44: 2377 - 2383. 
8. Chang, Y.C.; Nair ,M.G.; Santell, R.C. and W.G. Helferich . Microwave-mediated 
synthesis of anticarcinogenic isoflavones from soybean. J. Agric. Food. Chem. 1994; 42: 
1869-1871. 
79 
9. Farmakalidis E.; Murphy P.A. Isolation of 6"-0-acetylgenistin and 6"-0-acetyldaidzin 
from toasted defatted soyflakes. J. Agric. Food Chem. 1985;33: 385 - 389. 
10. Ollis W. D. The isoflavones. In: Geissman, T.A., ed. The Chemistry of Flavonoid 
Compounds. .MacMillan; New York. 1962: pp 353-405. 
11. Eldridge A.C. High-performance liquid chromatography separation of soybean 
isoflavones and their glucosides. J. Chromatog. 1982: 234: 494 - 496. 
12. Jones A.E.; Price K.R. and Fenwick G.R. Development of a high-performance liquid 
chromatographic method for the analysis of phytoestrogens. J. Sci. Food Agric. 1989: 46: 
357 - 364. 
13. Wang G.: Kuan S.S.: Francis O.J: Ware G.M. and Carman .^.S. simplified HPLC 
method for the determination of phytoestrogen in soybean and its processed products. J. 
.A.gric. Food Chem. 1990; 38: 185 - 190. 
14. Coward L.; Barnes N.C.: Setchell K.D.R. and Barnes S. Genistein, daidzein, and their 
p-glucoside conjugates : antitumor isoflavones in soybean foods from .American and Asian 
diets. J. Agric. Food Chem. 1993; 41: 1961 - 1967. 
15. Franke A. A.; Custer L.J.; Cema C.M. and Narala K.K. Quantitation of phytoestrogens 
in legumes by HPLC. J. Agric. Food Chem. 1994; 42: 1905 - 1913. 
80 
Aglvcones 
HO, 
OH 
Glucosidic forms 
CH2OR5 
OH 
OH 
OH 
2.4.4'-trihvdrox\deoi\"ben2oin (THB) 
R1 R2 Compound 
Daidzein 
Qpj |_j Genistein 
H OCH3 Glydtem 
R3 R4 Rf Compounds 
H H H Daidzm 
OH H H Genistm 
H OCH3 H Glycitm 
H H COCH3 Acerv Idaidin 
OH H COCH3 Acer> Igemsiin 
H 0CH3 COCH3 Acetylalycuin 
H H COCH2COOH Malonyldaidzm 
OH H COCH2COOH Malonv Igenistin 
H OCH3 COCH2COOH Malonylgiycitin 
Figure 1. Chemical structures of 12 isoflavone isomers and internal standard THB. 
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Figure 2. HPLC chromatograph of isoflavone isomers and THB in isolated soy protein. 
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Figure 4. Genistein as an external standard in dry tofu. 
Table 1. Standard curves of isoflavones 
Compound Source ^max 
(nm) 
Molecular weight Extinction coefficient (e ) working range ((ag / g) 
Dein synthesized by T. Song 249 254 26915 5 to 200 
Din purified by HJ. Wang 249 416 26915 5 to 200 
ADin adjusted from Din 256 458 31622 
MDin adjusted from Din 258 522 18197 
Gein synthesized by T. Song 263 270 31622 5 to 200 
Gin purified by HJ. Wang 263 432 31622 5 to 200 
AGin adjusted from Gin 261 474 32358 
MGin purified by HJ. Wang 260 518 16331 5 to 100 
Glein purified by T. Song 256 284 22387 5 to 100 
Glin purified by T. Song 259 446 26303 5 to 100 
AGlin adjusted from Glin 260 488 26303 
MGlin adjusted from Glin 260 532 26303 
Table 2. Comparison of isoflavone extraclion with water added to the extraction solvent 
Food sample Water added replications (n) Nomialized total Dein Normalized total Gein Normalized total 
(niL) (Hg/K)±S.D (Hg/g) ± S.D Glei (hh/h) ± S.D 
ISP" 0 2 248 ± 15 695 ±139 70 ±7  
ISP" 3 2 376 ± 15 801 ±29 80 + 21 
ISP" 5 4 417 ±49 844 ± 70 90 ± 20 
ISP" 7 3 439 ± 83 890 ± 129 97 ±32 
ISP" 10 3 445 ± 18 919 ±32 103 ±4  
Tofu 0 2 316±7 589 ± 11 55  ±8  
Tofu 3 2 431 ±7  759 ± 17 73  ±3  
Tofu 5 4 455 ±21 783 ± 28 75 ±2  
Tofu 7 3 485 ± 20 847 ± 36 79 ±3  
Tofu 10 3 504 ±3  841 ±2  79 ± 1 
Vinton Soybeans'" 0 5 362± 113 533 ± 114 55 ±9  
Vinton Soybeans'* 3 8 662 ±213 803 ± 178 85 ± 19 
Vinton Soybeans'' 5 6 815±46 923 ± 33 97 ±5  
Vinton Soybeans'' 7 3 850 ±41 959 ± 22 106 ±5  
Vinton Soybeans'' 10 3 778 ± 43 886 ± 59 90 ± 4 
a. ISP = Isolated soybean protein; 
b. 1994 crop. 
Table 3. Recovery of analyles and internal standard from spiked samples 
FOOD Compound 
Daidzein Genistein Genistin THB 
Recovery cv Recovery cv Recovery cv Recovery cv 
(mean ± (mean ± (mean ± (mean ± 
S.D.) {%) (%) S.D.) (%)  (%) S.D.) (%) (%) S.D.) (%) (%) 
TVP 91 ± 10 11.1  91 ± 6 7.4 98  ±5  6.1 97  ±3  2.9 
Soymilk 89  ±7  9.5 92  ±7  8.3 99 ± 6 6.7 98  ±4  4.6 
Soybean 74 ±9  11.8 93 ± 9 10.0 98 ± 2 2.4 101 ±4  3.7 
Tofu 91 ±7  8.1 89 ± 8 9.7 94  ±4  4.4 97  ±5  5.1 
T empeh 90 ±7  8.8 90 ± 7 8.6 97  ±5  5.3 97  ±4  4.5 
n =  1 0  
Table 4. Precision of analysis wilh Ihe proposed method for isoflavones from Vinton 81'' soybean 
Compound Mean (f.ig / g) Coefficient of variation (%) 
With in  assay  Between assay  
Daidzein 19.8 ± 1,4 1.7 7.2 
Daidzin 17.5  ±0 .8  3.2 4.9 
Acetyl-Daidzin 0.0 
Malonyl-Daidzin 1290.0154.2 1.7 4.2 
Genistein 18.3 ±0.8 1.5 6.1 
Genistin 221.3 ± 17.1 3.1 7.7 
Acetyl-Genistin 27.4 ± 1.0 2.0 3.6 
Malonyl-Genistin 1324.8 ± 100.0 2.2 7.6 
Glycitein 0.0 
Glycitin 51 .6  ±2 .8  3.6 5.6 
Acetyl-Glycitin 0.0 
Malonyl-Glycitin 127.1 ± 10.0 2.6 7.9 
a. 1994 crop. 
Table 5. Isoflavoiie contents (|.ig / g) of several soy foods 
Product Aglycone Glucoside Malonyl Acetyl Normalized Totar 
Dcin Gcin Glci Din Gin Glin Din Gin Glin Din Gin Glin Dcin Gcin Glci 
Vinton Sl^.d 21 22 0 163 178 50 1364 1467 137 0 29 0 811 914 105 1830 
IVpa 13 31 26 524 660 150 95 197 63 193 334 93 488 737 210 1435 
Roasted soybeans^ 44 77 58 474 568 70 46 65 74 40 71 54 379 506 174 1059 
Tofua.e 116 140 26 453 562 130 753 788 131 54 66 0 806 939 179 1924 
Fried Tofub'*-' 63 90 18 340 523 87 338 410 60 85 no 0 490 693 106 1289 
Roasted soyllour^' 18 16 13 470 584 ()2 956 885 46 1643 1375 56 1696 1626 109 3431 
Tenipeh^''^ 318 518 31 117 346 34 404 750 34 68 76 65 633 1168 109 1910 
Miso^ 61 3'J 11 157 122 37 1180 979 217 0 0 0 759 625 150 1534 
Soy niilk'^''^ 18 19 10 410 710 65 690 871 39 22 820 89 632 1384 124 2140 
Soy hot dogb 'J 18 y 36 69 16 13 43 16 0 4 15 38 86 36 160 
Soygerm'' 303 114 684 5208 1664 6505 3466 857 3313 10830 2616 3952 11204 3092 8905 23201 
Isd. 7 6 6 38 18 57 28 25 12 57 284 32 98 38 63 157 
a Data from three replications; b. Data from two replications; c. Adjusted for molecular weight; d. 1994 crop, 
e. Data based on dry samples weight. 
Isd. Least significant difference 
89 
ESTROGENIC ACIWITY OF GLYCITEIN, A SOY ISOFLAVONE 
A paper submitted to the Journal of Agricultural and Food Chemistry 
Tong T. Song'. Suzanne Hendrich' and Patricia A. Murphy' " 
Abstract 
Glycitein (4',7-dihydroxy- 6 -methoxyisoflavone) accounts for 5-10% of the total 
isoflavones in soy products. The biological activity of this compound has not been reported 
to date, although numerous studies have been performed with the other soy isoflavones, 
daidzein and genistein. Glycitein was isolated from soy germ to 99% purity. Weaning female 
B6D2FI mice were dosed with glycitein (3 mg/day), genistein (3 mg/day) and 
diethylstilbestrol (DES ) (0.03 jig/day) in 5% Tween 80 by gavage for 4 days. Control group 
received equal volume of 5% Tween 80 solution daily. The uterine weight increased 150% 
with glycitein (p < 0.001), 50% with genistein (p<0.00l) and 60% with DES (p<0.001) 
compared with the control group. DES, 17p-estradiol and three isoflavones (daidzein. 
genistein and glycitein) were examined for their competitive binding abilities with 17p-(^ H ) 
estradiol to the estrogen receptor proteins of the B6D2F1 mouse uterine cytosol. The 
concentrations of each compound required to displace 50% of the (^ H ) estradiol at 5 nM in 
the competitive binding assay were DES, 1.15 nM, ivp-estradiol, 1.09 nM, genistein, 0.22 
|aM, daidzein, 4.00 i^M and glycitein, 3.94 |iM. These data indicated that glycitein has weak 
estrogenic activity, comparable to the other soy isoflavones, but much lower than that of DES 
and 17p-estradiol. 
Key words: Isoflavone, Glycitein, Genistein, Daidzein, Phytoestrogen, Estrogenic activity. 
'Graduate student, professor, professor, respectively. Food Science and Human Nuoition, 
Iowa State University. 
"Author for correspondence. 
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Introduction 
Estrogens play important hormonal roles among all vertebrates. Animal estrogens are 
exclusively steroidal compounds, and the principal physiological estrogen in most species is 
17p-estradiol. Many plants produce compounds that possess estrogenic activity in animals 
and are, thus called phytoestrogens. These phenolic compounds have some structural 
similarity to the mammalian estrogen. 17P-estradiol. A common structural characteristic of 
these compounds is the presence of a phenolic ring, a prerequisite for the binding to the 
estrogen receptor (Figure 1). 
Soybeans contain the highest concentrations of isoflavones, at I -3 mg/g, as daidzein, 
genistein, glycitein and their corresponding glucosides, of foods consumed by humans. These 
soy isoflavones may have some important health-enhancing properties such as prevention of 
certain cancers (Barnes et al. 1991), lowering the risk of cardiovascular diseases (Anderson 
et al. 1995) and improvement of bone health (Bahram et al. 1996). The estrogenic activities 
of daidzein, genistein, and their glucoside forms, genistin and daidzin, were 100,000 to 
500,000 times lower than that of diethylstilbestrol (DES) (Farmakalidis and Murphy, 1985). 
Their estrogenic activity may play an important role in their health-enhancing properties. 
Genistein and daidzein account for the major portion of isoflavones in soy foods and have 
been the focus of niunerous studies. No biological studies on glycitein have been reported to 
date. However, glycitein accounts for 5 to 10% of the total isoflavones in soy foods, and may 
be as high as 40% in some soy supplements. Therefore, it is important to evaluate the 
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biological activity of glycitein. Since glycitein has a similar structure to genistein and 
daidzein, we hypothesize that it will have estrogenic activity comparable to them. 
There are a number of methods to assess estrogenic activity. Reel et al. (1996) 
proposed a test array for potential estrogenic activity. These methods can be grouped into 
four categories: (1) estrogen receptor binding, (2) estrogen receptor-dependent 
transcriptional expression, (3) reproductive tract response, and (4) non-reproductive-tract 
target tissue response. It is preferable to perform more than one assay to confinn the results. 
Estrogen receptor binding studies with soy isoflavones, genistein and daidzein, demonstrated 
they had the abilities to bind to estrogen receptors from different species including mice, rats 
and sheep (Verdeal et al. 1980). The binding affinities of these isoflavones were much lower 
than that of estradiol and DES. Farmakalidis and Murphy (1985) evaluated the estrogenic 
activity of genistin and daidzin. the isoflavone glucosides, and showed that the glucosides 
had equal estrogenic activity to the aglycones on a molar basis. The mouse uterine 
enlargement assay has been the standard in vivo method to evaluate estrogenic activity 
(Bickoff et al. 1962), and, since it is performed in an intact animal, the effects of absorption, 
metabolism, serum binding and pharmacokinetics are taken into account. 
iMaterials and iMethods 
Chemicals. DES. Tween 80, 17-P-(2,4-'H) estradiol (23 mCi / mmol), 17-P estradiol and 
dextran-coated charcoal (DCC) were obtained from Sigma Chemical Co. (St. Louis, MO). 
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ACS scintillation fluid was purchased from Fisher Scientific Inc. Glycitein was purified by 
the following method: 10 g soygerm (generously donated by Schouten USA. Inc., 
Minneapolis, .MN) was hydrolyzed in 100 mL 0.1 N HCl at 98°C for 2 hours, extracted with 
acetonitrile and filtered through Whatman No. 42 filter paper. The filtrate was dried by a 
rotary evaporator at 50 °C. The residue was dissolved in 80% ethanol and applied to a 
Sephadex LH-20 column (2.5 cm x 50 cm) with 50% ethanol as the eluent. The glycitein 
peak was collected and freeze-dried. Genistein was purified from soybeans using the same 
procedure as glycitein. Daidzein was chemically synthesized according to Song et al (1998). 
The identification and purity of glycitein. daidzein and genistein were confirmed by HPLC. 
ultraviolet (UV) spectral analysis, melting point and mass spectrum analysis. Glycitein. 
daidzein and genistein were analyzed by HPLC on a Beckman System Gold chromatography 
system including a .Model 507 autosampler. a .Model 126 dual pump, a Model 168 
photodiode array detector and an IBM 486 computer with Beckman Gold system HPLC data 
processing software (version 8. 1993) according to Miuphy et al. (1997). .A \'MC-pack 
ODS-AM-303 column (5 |am. 25 cm x 4.6 mm) (YMC Inc. Wilmington, NO was used. LTV 
spectral analysis was performed according to .Marbr>' et al. (1970) using a Beckman DU 7400 
spectrophotometer. The melting point was measured with a Perkin Elmer 7 series differential 
scanning calorimeter (DSC) (Perkin Elmer Inc. Norwalk, CT). Mass spectrum analysis, 
using chemical ionization, was performed on a Finnigan model TSQ-700 mass spectrometer 
(Finningan Inc. Piscataway. NJ). 
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Animals and treatments. The mice uterine enlargement assay was performed according to 
Farmakalidis and Murphy (1985). Inbred B6D2F1 mice were obtained from Harlan Sprague-
Dawley (Madison, WI). Each dam was housed separately with her female pups (14 days old 
on arrival), and the mice received AIN-93 M diet (Reeves et a!., 1993) and water. Pups were 
weaned at 21 days of age. The mice were randomly assigned to treatment groups (control. 
DES. genistein and glycitein) of 20 mice. An AIN 93-G diet and water were provided. The 
diet contained no soy isoflavones. Genistein, DES and glycitein were suspended in 5% 
Tween 80 and were administered to the mice by gavage needle in four daily doses of 0.1 ml 
suspension / day beginning on the day after weaning for 4 days. The total doses were 0.12 
jig DES / mouse or 12 mg genistein or glycitein / mouse. The control group was given 0.1 
ml of 5% Tween 80 for four days. At twenty-four hours after the last dose, mice were 
weighed and sacrificed under CO.. Their uteri were dissected out, and the wet weights were 
obtained immediately. Mouse uteri were homogenized, and cytosols were prepared for 
estrogen receptor binding assay as described below. The blood from genistein and glycitein 
groups was collected by using cardiac puncture. Plasma was prepared by centrifligation at 
5000 g for 10 min at 4°C and kept frozen until analysis of plasma isoflavones. The animal 
experimental protocol was approved by Iowa State University Animal Use Committee. 
Tissue handling and estrogen receptor assay. The estrogen-binding assay was modified 
from Verdeal et al. (1980). Mouse uteri were homogenized (Brinkmann Instruments, 
Rexdale, Canada) in 10 mM Tris and 1 mM EDTA, pH 7.4 buffer (1:10 wt/vol). The cytosol 
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fractions were obtained by centrifugation of the homogenate at 100.000 g for 1 hour. Total 
binding was determined by adding 0.2 ml each of 1 mM EDTA. pH 7.4 buffer. ("H) estradiol 
(1.5 ng / ml in I mM EDTA pH 7.4 buffer), and cytosol fraction. Non-specific binding was 
determined by replacing the I mM EDTA buffer with 0.2 ml of 17p-estradioI (1500 ng mi 
in the 1 mM EDTA. pH 7.4 buffer). Blanks contained 0.4 ml of 1 mM EDTA buffer and 0.2 
ml ("H) estradiol. Competitive binding was determined by replacing the 0.2 ml buffer in the 
total binding mixture with 0.2 ml of solution containing the different estrogens at appropriate 
concentrations in 1 mM EDTA. pH 7.4 buffer. Duplicates were performed for each estrogen 
at each concentration. Samples were incubated at room temperature (23°C) for two hours. 
One half ml of 2.5% DCC in 1 mM EDTA buffer was added to all mi.xtures after incubation. 
The samples were mixed, incubated for 15 min. and centrifiiged at 1000 g for 10 min. .After 
centrifiigation. the supematants were decanted into scintillation vials containing 10 ml ACS 
scintillation fluid. The samples were counted for 10 minutes on a Packard liquid scintillation 
analyzer model 1900TR (Packard Instrument Co., Downers Grove, IL). 
Plasma isoflavone analysis: Plasma samples of the genistein and of the glycitein group 
were combined to give one pooled sample for each treatment. Two ml of 0.2 M sodium 
acetate pH 5.5 buffer, 100 }aL of P-glucouronidase/sulfatase and 20 i^L of 4 mg/ml internal 
standard, 2,4,4'-trihydroxydeoxybenzoin (THB) (Song et al 1998), were added to 2 ml of 
plasma sample. The mixture was incubated at 37°C for 16 hours. Six ml of methanol was 
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added to the mixture, mixed well and centrifiiged at 10.000 g for 20 min. Eight ml of 
supernatant was brought to dryness and dissolved in 400 |a,l of 80% methanol. After 
centrifligation. 20 uL of sample was taken for isoflavone analysis in our HPLC system. The 
HPLC conditions were the same as in identification of genistein and glycitein stated above. 
The minimal detection level by L"V' detector at 254 run for genistein and glycitein was 0.5 
)i.g/ml or 1.9 jiM in injection solution. 
Statistical analysis. The uterine enlargement data were analyzed by using a one-way 
classification analysis of a completely randomized design (SAS version 6. SAS Institute Inc. 
Box 8000. Cary. NC) at a= 0.05. 
Results and Discussions 
The purity of glycitein and genistein was confirmed by HPLC. L'V' spectral analysis, 
melting point and mass spectrum analysis. The HPLC chromatography of glycitein showed 
one single peak and the purity of glycitein was confirmed by peak area percentage and peak 
purity program to be > 99%. Nairn et al.( 1973) first isolated glycitein firom soybeans and 
reported UV specnral data of glycitein. The L'V spectral data for our glycitein were: k 
(methanol) 257, 319 nm; ( sodium methoxide ) 259, 344 nm; (AlCl -,) 257. 317 nm; 
(AICl 3 - HCl) 257. 317 nm; (sodium acetate) 255, 346 nm; /i (sodium acetate-
H3BO3) 255, 320 nm. These data were the same as reported by Naim et al. (1973). The 
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molecular weight of our glycitein from the mass spectrum analysis was 284, which matched 
the mass reported by Naim et al (1970) and the calculated molecular weight of glycitein. The 
melting point of glycitein measured by DSC was 337 - 339 °C. This melting point differed 
from that reported by Naim et al. (1973) of 311 - 313 °C. Recently, Nogradi and Szollosy 
(1995) chemically synthesized glycitein and reported a melting point of 337 - 339 °C. The 
purity of genistein was confirmed to be greater than 99% by using the similar method for 
glycitein. 
In our preliminary study, we used chemically synthesized genistein (Chang et al.. 
1994) as one of the positive controls and did not obtain any estrogenic response from the 
mice uterine enlargement assay. However, we did get estrogenic responses from glycitein 
and DES. We evaluated the purity of the synthesized genistein and found that it contained a 
contaminant which co-eluted in our analytical HPLC system with authentic genistein. .A. 
broad melting point thermogram indicating a mixture of genistein and the contaminant was 
detected by DSC analysis. To avoid this problem, we purified the genistein from soybeans 
for the present study. 
The uterine enlargement assay yielded significant differences (p < 0.001) in uterine 
weights among treatments (Table I). The glycitein, genistein and DES group had 150%, 
50% and 60% greater uterine weight, respectively, compared with the control. The relative 
estrogenic potencies of DES, genistein and glycitein were 100,000, 1, and 3, respectively 
(Table 1). The relative estrogenic potencies of DES, glycitein, and genistein were estimated 
based on the doses required to produce the same increase of uterine weights. The relative 
97 
estrogenic potencies of genistein and DES from the present study were similar to the results 
of Farmakalidis and Murphy (1985), where the relative molar potencies of DES, genistein, 
genistin and daidzin were 100,000, 1, 1 and 0.26. respectively. The present study 
demonstrated that the estrogenic potency of glycitein in mice uterine enlargement assay was 
three times higher than that of genistein, but, as hypothesized, was much lower than that of 
DES. 
It is generally assumed that nonsteroidal estrogens exert their stimulatory effect on the 
estrogen receptor by binding to the same site as that occupied by steroidal estrogens such as 
17p-estradiol. Our competitive binding study results are shown in figure 2 where increasing 
concentrations of unlabeled competitors displace bound (^H) estradiol. These results confirm 
that glycitein has the ability to bind to the estrogen receptor. DES had much higher binding 
affinity compared with that of the three isoflavones. The relative affinities of these 
compounds for the mice estrogen receptor were calculated by dividing the CB 50 of unlabeled 
I7p-estradiol by the CB joOf competitor and then multiplying by 100 (table 2). These data 
reconfirmed that both DES and estradiol had much greater binding affinity to estrogen 
receptor than the three isoflavones. Among the three isoflavones, genistein had the greatest 
estrogen receptor binding affinity. The in vitro estrogen receptor binding data in this study 
was comparable to the previous results summarized by Verdeal et al. (1980). They reported 
that genistein had binding affinity roughly 100 times lower than 17p-estradiol, and daidzein 
had binding affinity 10 to 15 times lower than genistein. 
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The plasma extraction and analysis recovery was 85% for internal standard THB. 
The recovery-corrected plasma isoflavone concentration for genistein-treated and glycitein-
treated group pooled sample was 0.42 |aM and 0.72 [aM, respectively. Xu et al. (1994) and 
King et al. (1995) have reported in humans and in rats that 4 to 6 hours after isoflavone 
dosing, daidzein and genistein reached maximal concentrations in plasma, then decreased 
thereafter. .A.t 24 hours after dosing, there were only trace concentrations of daidzein and 
genistein in the plasmas. Since we collected blood 24 hours after the last dose of isoflavones. 
the low plasma isoflavone concentrations may be the result of rapid excretion of isoflavones 
after dosing. 
Glycitein gave a much lower in vitro binding affinity compared to genistein in the 
estrogen receptor-binding assay. However, it gave higher estrogenic response in the in vivo 
mice uterine enlargement assay. This could be explained by the probable higher 
bioavailability of glycitein compared to genistein in mice. In a human isoflavone metabolic 
study, a higher bioavailability of glycitein than genistein was demonstrated (Zhang, Hendrich 
and Murphy, unpublished data). This may be the case in mice as well. Another possible 
explanation is that genistein may be metabolized to certain compounds that have lower or no 
estrogenic activity. Shutt et al (1970) reported that genistein could be metabolized to p-
ethylphenol, which is not an estrogenic compound. It is possible that glycitein may be 
metabolized to certain compounds with greater estrogenic potency than the parent compound. 
Daidzein has been reported to be a less effective estrogen than genistein when fed to 
mice (Bickoff et al. 1962). Our present study demonstrated that glycitein is a stronger 
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estrogen in mice uterine enlargement assay compared to genistein. Of the three soy 
isoflavone aglycones, it appears that glycitein has the highest estrogenic potency in the in 
vivo estrogen assay, although it has relatively lower binding affinity to estrogen receptor than 
genistein. The in vitro binding affinity to estrogen receptor is not the only factor determining 
the in vivo potency of the estrogen. There are other factors, such as absorption and 
metabolism, which would also be important. 
This study has demonstrated the in vivo estrogenic activity and the in vitro binding 
affinity to estrogen receptors of glycitein. These data reveal that, although glycitein accounts 
for about 10% of the total isoflavones in soy foods, its biological potency should not be 
neglected. Development of soybean and soy food isoflavone databases cannot ignore 
glycitein and its glucosides. .Additionally, the bioavailability, metabolism and other health 
protective aspects of glycitein and its glucosides need to be explored. 
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Table 1. Estrogenic activities of soy isoflavones in mice 
Treatment Uterine weight Body weight Relative 
(mg) is} Potency^ 
Compound Total No. of Mean ± SEM Initial Final 
dose (mg) mice 
Control 0 20 17.7± 0.9" 8.1 11.6 
DES 0.12x10"' 20 28.5± 1.1" 8.1 11.7 100.000 
Glycitein 12 20 44.6±3.r 8.3 12.1 3 
Genistein 12 20 26.4±1.0'' 8.2 11.7 I 
Uterine weight means bearing different letters are significantly different, 
p<0.05. 
a- The relative potency was calculated based on the doses of estrogens 
required to produce a 10-mg increase of uterine weight. 
Table 2. Relative affinities of estrogens for estrogen receptors •* 
Compounds CB ,o(p iM) Relative affinity 
17P-estradiol 0.00109 100 
DES 0.00115 95 
Genistein 0.223 0.49 
Daidzein 4.00 0.027 
Glycitein 3.94 0.028 
\ Based on the molar concentrations (CB 5,,) required to displace 50% of the (^H) estradiol. 
n=2. 
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Estrodioi OH 
HO' 
Diethyistilbestrol 
OH 
HO 
Soy isoflavones R1 R2 
Daidzein H H 
Genistem H OH 
Glycitem OCH3 H 
OH 
HO 
Figure 1. Chemical structures of soy isoflavones, IVP-estradiol and diethystilbestrol. 
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Genistein 
Glycitein 
Daidzein 
Estradiol 
0 12 3 4 
log (fold excess of (3H)estradiol) 
Figure 2. Competitive binding analysis of isoflavones. Cytosol from mice uteri were 
incubated with 1.5 ng/ml 17p-(^H)estradiol in die presence of increasing 
concentrations of unlabeled estrogens. n=2. 
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SOY PROTEIN, WITH OR WITHOUT ISOFLAVONES, AND DAIDZEIN LOWER 
PLASMA CHOLESTEROL LEVELS IN GOLDEN SYRIAN HAMSTERS 
A paper to be submitted to the Journal of Nutrition 
Tongtong Song'. Sun-ok Lee', Patricia A.Murphy' " and Suzanne Hendrich' 
Abstract 
The plasma cholesterol lowering effects of dietary isolated soy protein (ISP), 
isoflavone-depleted ISP (ISP (-)). daidzein or soygerm were investigated using Golden 
Syrian hamsters. Sixty males and 60 females were randomly assigned to six different groups 
(n=10) and fed for 10 weeks. The six experimental diets were casein control. ISP, ISP(-). 
daidzein. soygerm or soygerm extract to give a total isoflavone content of 1.3 mmol/kg diet 
(except for casein and ISP(-) groups). ISP (-) diet had 0.013 mmol isoflavone kg diet. All 
hamsters fed ISP, ISP (-). daidzein, soygerm and soygerm extract had significantly lower 
plasma total cholesterol (16% to 28% lower), LDL cholesterol (15 to 50% lower) and 
LDL/HDL ratios compared with the control group (p<O.Ol). For male hamsters, there were 
no differences among treatments in plasma HDL concentrations. For females. ISP and ISP 
(-) groups had significantly higher HDL levels (20 to 30% higher) (p<O.Ol) than the casein-
based treatments. There were no differences in triglyceride levels among treatments for both 
genders. These data suggested that soy protein, with or without isotlavones. the soy 
isoflavone daidzein and soygerm have cholesterol-lowering effects in hamsters. 
Key words: Isotlavones. daidzein. soygerm. soy protein hamsters, cholesterol, cholesterol-
lowering effects. 
'Graduate student, graduate student, professor, professor, respectively. Food and Human 
Nutrition, Iowa State University. 
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Introduction 
An elevated plasma level of LDL-cholesterol represents a major risk factor for the 
development of atherosclerosis (Newman et al, 1986). While dietary intake of cholesterol 
and saturated fat raise the plasma LDL-cholesterol levels, there are a number of dietary 
factors, such as dietary fiber or soy protein, that can counteract these effects. Consumption 
of soy protein, in place of animal protein, has been reported to decrease serum total and 
LDL-cholesterol concentrations in humans (Mercer et al., 1987; Gooderham et ai, 1996 and 
Bakhit et al., 1994) and in animals including rats, hamsters, guinea pigs, monkeys and 
baboons (Terpstra er a/., 1991; Potter era/., 1996; Campbell etal. 1995)). A meta-analysis 
of the effects of soy protein intake on serum lipid levels (Anderson et al 1995) showed a 
significant relationship between soy intake and lower levels of total and LDL- cholesterol 
and lower risk of coronary heart disease, one of the leading causes of death in the United 
States. However, the components of soy responsible for these cholesterol lowering effects 
have not been determined. 
The amino acid composition of soy protein was investigated for its effects on plasma 
lipids. Huff et al (1977) reported that soy protein or an enzymatic hydrolysate of soy protein 
compared with casein lowered plasma total cholesterol and LDL-cholesterol levels in rabbits. 
Soybean protein amino acid reconstitutions were not as effective in lowering plasma 
cholesterol as the intact protein. Casein amino acid reconstitution induced a similar effect on 
plasma cholesterol levels as the intact casein (Huff and Carroll, 1980). Several reports have 
suggested that other non-protein components in soy, including soy isoflavones. soy saponins, 
dietary fiber and soy phenolic acids may be the possible factors for soy protein's 
hypocholesterolemic effect (Carroll, 1991; Setchell, 1985; Anthony etal., 1995). 
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Setchell (1985) suggests that isoflavones. the soy phytoestrogens, may contribute to 
the cholesterol-lowering effect. Soybeans and soy foods are the major source of isoflavones 
in human diets, as daidzein. genistein. glycitein and their glycoside forms, at concentrations 
from 0.25 to 3 mg/g (Wang and Murphy. 1994). Soy isoflavones have weak estrogenic 
activities (Bickoffe/' a/.. 1962: Farmakalidis and Murphy. 1985; Verdeal et al.. 1980; Song et 
al., 1998). Soy isoflavones may have effects similar to other estrogens. The administration 
of oral estrogens or the synthetic anti-estrogen, tamoxifen, decreased total serum cholesterol 
and LDL-cholesterol levels in postmenopausal women (Walsh et al.. 1991; Love et al.. 
1991). Lovati et al (\99\) reported that an ethanol extract from soy protein reduced serum 
LDL-cholesterol levels and increased LDL receptor activity in mice. The ethanol extract 
contained soy isoflavones and soy saponins. .Anthony et al. (1995) tried to address the 
question of whether isoflavones are responsible for the cholesterol-lowering effects of soy 
protein. They showed that an isoflavone-rich soy protein diet significantly lowered the total 
(15% to 20%) and LDL (30% to 40°'o) cholesterol levels in both male and female colony-
bom Rhesus monkeys when compared with ethanol-extracted soy protein from which more 
than 90% of the isoflavones had been extracted. Recent studies by Balmir et al. (1996) 
showed that soy isoflavone extracts, which contained 50-60% isoflavones. when added to 
diets with casein as protein source, significantly lowered the total (10% to 20%) and LDL (20 
to 30%) cholesterol levels in rats and hamsters compared with the casein control group. 
These data are consent with the hypothesis that the observed hypocholesterolemic effect of 
soy protein is due to the soy isoflavones. However, none of these studies used piuified 
isoflavones. The ethanol-acetone extracts from soy proteins contain, in addition to 
isoflavones. other ethanol-acetone soluble compounds including soy saponins and soy 
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phenolic acids. Soy saponins are a group of phytochemicals at concentrations comparable to 
isoflavones and have been associated with a hypocholesterolemic effect (Potter et al.. 1993). 
We hypothesize that soy isoflavones are the major hypocholesterolemic factor in soy. 
To test this hypothesis, we fed purified isoflavones to hamsters. Golden Syrian hamsters 
were selected because there are several general similarities in cholesterol metabolism 
between hamsters and humans, including a low basal rate of hepatic cholesterol synthesis and 
a comparable bile acid pool composition (Spady and Dietschy, 1985; Spady et al 1985; 
Bravo et al.. 1994). In addition, hamsters fed a diet enriched with cholesterol and saturated 
fat manifest substantial increase in their plasma total and LDL-cholesterol levels, thus, 
making these species a good model to assess cholesterol metabolism (Terpstra et al.. 1991). 
Materials and methods 
Chemicals and Diets. The isoflavone, daidzein. was chemically synthesized 
according to Song et al. (1998). The purity of daidzein. determined by HPLC chromatograph 
peak area percentage and Beckman Gold HPLC System peak purity software, was >98%. 
Soygerm was generously donated by Schouten USA. hic. (Miimeapolis, MN). Isolated soy 
protein (ISP) was purchased from Protein Technology International (St. Louis, MO). The 
soygerm extract was prepared by using ethanol and acetone extraction according to Balmir et 
al. (1996). The isoflavone- free isolated soy protein (ISP (-)) was prepared by extracting ISP 
with 70% ethanol at weight to solvent ratio of 1 g ISP; 4 ml of aqueous ethanol four times. 
The isoflavone contents in ISP, soygerm. soygerm extract and ISP (-) were analyzed by using 
HPLC method (Murphy et al., 1997). The molar concentrations of daidzein and total 
isoflavones were presented in Table 1. 
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The control diet for hamsters was based on Terpstra et al (1991). There were six 
different diet treatments: casein control. ISP. ISP (-), daidzein, soygerm or soygerm extract. 
Daidzein, soygerm and soygerm extract diets were casein-based. The diets were formulated 
to contain the amount of daidzein. soygerm, or soygerm extract, which would equal the total 
molar isoflavone contents in ISP, 1.3 mmol/kg diet. Experimental diet composition is shown 
in Table 2. Cholesterol at 0.1% level was formulated into the diet. Rice flour was used as 
carbohydrate source to replace cornstarch in normal rodent diet because rice flour essentially 
eliminates "wet tail" disease, a form of chronic diarrhea and accompanying high rate of 
mortality for hamsters (Terpstra et al., 1991). 
Animals. The animal experimental protocol was approved by Iowa State University 
Animal Use Committee. 
Sixty male and 60 female Golden Syrian hamsters, 6-8 week old, weighing between 
100 and 110 g were obtained from Charles River Breeding Laboratories 
(St. Constant, Canada). They were housed individually in a temperature-controlled room 
(23°C) with a l2-h light; dark cycle. Males and females were kept in separate rooms. Upon 
arrival, hamsters were fed a powdered AIN 93 M diet for one week to acclimate ammals to 
the facility and powdered diets. Hamsters were randomly assigned to one of the six diet 
treatments with 10 male and 10 female animals per treatment. Hamsters had free access to 
food and water during the 10-week experimental period. At the end of the feeding period, 
diets were withdrawn from hamsters 14-16 hrs before they were sacrificed under CO2. Blood 
was collected by using cardiac puncture. Plasmas were prepared by centrifugation at 5000 g 
for 10 min at 4°C and kept frozen at -20°C until analysis. 
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Plasma lipid analysis: Plasma total cholesterol, HDL cholesterol and triglyceride 
(TAG) concentrations were measured by using Sigma diagnostics kits (St Louis, MO). LDL 
cholesterol was calculated by subtraction of HDL cholesterol from total cholesterol and 
represented LDL+IDL-'-VLDL cholesterol. 
Plasma isoflavone analysis: Plasma samples were combined within each group to 
give two pooled samples for each treatment. Two ml of 0.2 M acetate buffer (pH 5.5), 100 
(il of P-glucouronidase/sulfatase and 10 ji! of 4 mg/ml internal standard 2,4,4'-
trihydroxydeoxybenzoin (THB) (Song et al., 1998) were added to 2 ml of plasma sample. 
The mixture was incubated at 37°C for 16 hours. Six ml of methanol was added to the 
mixture, which was mixed well and centrifuged at 10,000g for 20 min. Eight ml of 
supernatant was brought to dryness and redissolved in 400 |j,l of 80% methanol. After 
centrifugation, 20 fil of sample was taken for isoflavone analysis. A Beckman System Gold 
chromatograph with a Model 507 autosampler, a Model 126 dual pump, a Model 168 
photodiode array detector, and an IBM 486 computer using Beckman System Gold HPLC 
data processing software (version 8, 1993) was used. A YMC-pack ODS-AM-303 analytical 
cokmin (5 jim, 25 cm x 4.6 mm) was used for the chromatographic separation. A linear 
gradient was composed of solvent A (0.1% acetic acid in water) and solvent B (0.1% acetic 
acid in acetonitrile). After injection of 20 |^1 sample, the system was maintained at 15% B 
for 5 min, then increased to 29% in 31 min, and then to 35% in 8 min. The system was 
recycled to 15% at the end of 45 min. The flow rate was I.O ml/min for the first 5 min, then 
increased to 1.5 ml/min for the next 40 min, and retumed to 1 ml/min for recycle. The 
minimal detection level for daidzein, genistein and glycitein was 1.6 |4.M in the injection 
I l l  
solution by UV detector at 254 nm. The recovery of the extraction and analysis based on the 
internal standard THB was 85%, and the recovery-adjusted plasma isoflavone concentrations 
were reported. 
Statistical analysis: All data were analyzed by using two-factor ANOVA (SAS 
version 6.03. SAS Institute, Cary, NC). Since there were no interactions between gender and 
treatments, all analyses were redone separately for each gender by one-way ANOVA. 
Differences between treatments were determined by the least significant difference test. A a 
of 0.05 was used to indicate statistically significant differences. 
Results 
The powdered diets were well accepted by hamsters throughout the experiment. 
Food intakes were 7.3± 0.4 g/day and 7.6 ±0.4 g /day for males and females, respectively. 
Final body weights were 142±I0 g and 154±10 g for male and female hamsters, respectively. 
The weight gain was 40±3 g for males and 52±4 g for females. There were no final weight or 
food intake differences among dietary treatment groups for females. For males, there were 
no food intake differences, however, the casein+daidzein diet treatment had 10% lower final 
body weight (p<0.05) compared with other treatment groups. 
Two-way ANOVA showed that there no interactions between diets and genders on 
total cholesterol, HDL cholesterol, LDL cholesterol and TAG levels. Therefore, we analyzed 
the results for males and females separately and the results were summarized in Table 3 for 
male hamsters and in Table 4 for female hamsters. Total cholesterol, LDL-cholesterol levels 
and LDL/HDL ratios were significantly lower (p<0.01) in the ISP, ISP (-), daidzein, 
soygerm, and soygerm extract diet treatment groups compared with the casein control diet in 
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both males and females. There were no differences among treatments in HDL cholesterol 
levels in males. However, ISP and ISP (-) groups had 30% higher HDL cholesterol levels 
(p<0.01) compared with the casein-fed hamsters in females. There were no differences in 
TAG levels among treatments for both genders. 
Plasma isoflavone levels: The plasma isoflavone levels (fiM) were summarized in 
Table 5. Daidzein. genistein, glycitein and equol, the metabolite of daidzein, were detected 
in most of the male hamster plasma samples but only in a few of the female samples, ranging 
from 0.4 to 3.6 |aM. 
Discussion 
In a preliminary experiment, we used pure chemically synthesized isoflavones, 
daidzein and genistein, to examine their possible cholesterol-lowering effects in male 
C57BL/6 mice. A 0.1% cholesterol-enriched, 20% fat, casein-based diet was used. The 
isoflavone levels in the diets were: 0.6 mmole or 1.2 mmole daidzein/Tcg diet, 0.6 mmole or 
1.2 mmole genistein/kg diet, or 0.6 mmole daidzein -^0.6 mmole genistein/kg diet. This 
preliminary data showed that either daidzein or genistein at 1.2 mmole/kg diet, or 0.6 mmole 
daidzein + 0.6 mmole genistein/kg diet, appeared to lower total plasma cholesterol levels by 
8 to 10%, but were not different from the control (p>0.1). The LDL-cholesterol levels were 
significantly reduced by the 1.2 mmole daidzein /kg diet and the 0.6 mmole daidzein -f- 0.6 
mmole genistein -leg diet (p<0.01). There were no significant differences among dietary 
groups in HDL cholesterol and TAG levels. These preliminary data suggested the possible 
activity of daidzein in lowering plasma cholesterol levels, especially LDL cholesterol. 
The hamster has been identified as the rodent species most closely related to humans 
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in lipoprotein metabolism (Spady and Dietschy, 1985; Bravo et al (1994) and has been 
suggested as a better animal model to study cholesterol metabolism than the mouse or rat. 
Terpstra et al. (1991) reported that the LDL fraction of the lipoproteins in hamsters fed 0.1% 
cholesterol-enriched diet was around 40-50% of the total cholesterol. However, in the mouse 
or rat, the LDL portion only represented 20-30% of the total cholesterol (Balmir et al.. 1996). 
The data from our preliminary study suggested that the decrease in total cholesterol levels by 
the daidzein dietary treatment in mice was due principally to the decrease in the LDL portion. 
In order to confirm this hypothesis that isoflavone daidzein can decrease total cholesterol, 
and especially, the LDL portion, it may be better to use hamsters as the model. In the present 
study, we chose hamsters as the animal model to examine the cholesterol-lowering effect of 
daidzein. 
The data from the study reported here suggested that the dietary protein source and 
the dietary soy isoflavones influenced the plasma cholesterol levels in hamsters. Daidzein, in 
a casein-based diet, significantly reduced total cholesterol, LDL-cholesterol levels and the 
LDL/HDL ratios. This study confirmed our hypothesis that the soy isoflavone, daidzein, was 
a major factor contributing to soy protein's cholesterol-lowering effects. 
Decreases in plasma total and LDL-cholesterol levels were observed in hamsters fed 
isoflavone-intact soy protein compared with the casein control group. However, the removal 
of isoflavones from soy protein gave the similar plasma cholesterol lowering effects. These 
results were similar to that of Balmir et al. (1996) where soy protein, with or without soy 
isoflavones, had the ability to lower plasma cholesterol levels in rats. These data suggested 
that, in addition to isoflavones, there were other factors in soy protein capable of producing 
cholesterol-lowering effects. Our finding of the similar cholesterol lowering effects of ISP 
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and ISP (-) suggested that the cholesterol-lowering effects can not be attributed to 
isoflavones alone. Additionally, the cholesterol lowering effects of soy protein or soy 
isoflavones appeared to reach a plateau. This plateau was observed by Tovar-Palacio et al 
(1998) where they reported that soy protein lowered plasma cholesterol levels in the gerbil 
compared with the casein control. But when isoflavone extracts were added to the soy 
protein diet at three different doses of 8.0, 13.8 or 23.8 |imol isoflavone / g protein, they did 
not reduce cholesterol levels further than soy protein alone. However, these diets 
significantly reduced cholesterol levels compared with the casein control group. They 
suggested that the cholesterol-lowering effects might have reached a plateau or maximum. In 
the current study, both the soy protein level and isoflavone level may have caused plasma 
cholesterol lowering to reach a plateau level. There was no additive effect for dietary soy 
protein and soy isoflavones. If lower soy protein levels or lower isoflavone levels were used, 
the additive effects may be revealed 
Soygerm, the hypocotyl portion of the soybean seed, is a naturally concentrated soy 
isoflavone product. Soygerm has a unique isoflavone profile, with daidzein accounting for 
50% of the total isoflavones, glycitein for 35%, and genistein only for about 15%. This 
profile is very different firom intact soybeans, where genistein accoimts for 50% of the total 
isoflavones and glycitein for only 5 to 10%. The total isoflavone concentration in soygerm is 
20-30 mg/g, much higher than soybeans or typical soy foods at 0.25 to 3 mg/g. Our study 
demonstrated the same magnitude hypocholesterolemic effect of soygerm and soygerm 
extract as for ISP, ISP (-) or daidzein. 
Dietary soy protein has been reported to enhance bile acid excretion compared with 
casein in rabbits and rats (Potter, 1996). The hepatic cholesterol metabolism shifts to provide 
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cholesterol for enhanced bile acid synthesis and the rate of cholesterol removal from blood 
was increased, resulting in plasma cholesterol level reduction. Nagata et al (1982) reported 
increases in total, neutral and acidic fecal bile acids and decreases in plasma total and LDL-
cholesterol levels in rats fed soy protein. 
The cholesterol lowering effects observed in the present study were mainly due to the 
decrease in the LDL-cholesterol. The steady state plasma LDL-cholesterol concentrations 
have been determined by four separate variables: the maximal rate of receptor-mediated 
uptake of LDL-cholesterol by the tissues, the rate of LDL-cholesterol production, the affinity 
of the LDL molecule for its receptor and the rate of LDL-cholesterol uptake through an LDL-
receptor independent process (Meddings and Dietschy, 1987). Soy protein and soy 
isoflavones may influence the plasma LDL-cholesterol levels through any one of these 
factors. Lovati et al (1998) reported that P-conglycinin (7S globulin) from soy has the ability 
to up-regulate LDL receptor activity in human hepatoma cell line culture. Their results 
suggested that soy protein might increase the clearance of LDL-cholesterol by increasing the 
activity of LDL receptor. Kirk et al(\ 998) reported that dietary soy protein with isoflavones 
(1.33 mmol/kg diet) reduced plasma LDL-cholesterol levels (30%) in C57BL/6 mice 
compared with the isoflavone-depleted soy protein. In the same study, they found no 
cholesterol lowering effects of isoflavone-containing soy protein in the LDL receptor-
deficient mice. This data suggested that the influence of isoflavones on LDL-cholesterol 
levels were not mediated through the LDL-receptor independent pathway. Instead, soy 
isoflavones might lower LDL-cholesterol by increasing the activity of LDL receptor, and 
thus, the clearance of LDL-cholesterol. The possible effects of isoflavones on LDL-
cholesterol production, which usually occurs with the intake of diet enriched with saturated 
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fat and cholesterol, should be investigated. Additionally, how isoflavones may affect the 
LDL receptor activity is very important in elucidating the mechanisms of isoflavone's 
cholesterol-lowering effects. 
We detected all three isoflavones and equol in the plasma samples, ranging from 0.4 
to 3.6 jiM, which were similar to the levels detected in human plasma (Xu et al., 1994) and 
rat plasma (King, et al.. 1995). We found both daidzein and its metabolite-equol in plasma 
of daidzein-treated groups, which suggested that hamsters had the ability to metabolize 
daidzein to equol. While isoflavones were detected in most of the male hamster plasma 
samples, only a few females had detectable plasma isoflavone levels. This suggested that 
there might be a gender difference in isoflavone absorption and metabolism in hamsters. 
The plasma cholesterol-lowering activity for the other isoflavones, genistein and 
alvcitein, as well as the combinations of these three isoflavones, needs to be examined. The 
possible cholesterol lowering effects of soy isoflavones suggests there is potential to use 
these soy components as dietary cholesterol lowering agents. 
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Table 1. Isoflavone concentrations^ in different diet components. 
Components Daidzein Genistein Glycitein Isoflavone content ' 
(jimol / g) (^imol/g) (|imol / g) ( ^mol g) 
ISP (Supro-670 ") 1.9 2.9 0.4 5.2 
Soygerm 36.3 9.9 25.6 71.8 
Soy germ extract 336.2 82.2 310.4 728.8 
ISP (-) 0.015 0.02 0.015 0.05 
1. The total mole concentration of isoflavone was calculated as the sum of mole 
concentrations of daidzein. genistein and glycitein. 
2. Isolated soy protein Supro-670 was purchased from Protein Technologies International 
(St. Louis, MO). 
3. Minimum detection level was 1 fimole g sample. 
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Table 2. Composition of experimental diets (g / kg) 
Ingredient Casein ISP ISP (-) Daidzein Soygerm Soygerm extract 
Casein' 250 0 0 250 250 250 
ISP 0 250 250 0 0 0 
Coconut oil 100 100 100 100 100 100 
Safflower oil 20 20 20 20 20 20 
Soybean oil 40 40 40 40 40 40 
Cellulose 75 75 75 75 75 75 
Wheat bran 75 75 75 75 75 75 
Choline chloride J 3 3 J 3 J 
Vitamin mix" 10 10 10 10 10 10 
Mineral mix" 35 35 35 35 35 35 
Potassium 
bicarbonate 20 20 20 20 20 20 
Cholesterol I I 1 1 I 1 
Rice flour"^ 371 371 371 370.67 353 369.22 
Daidzein 0 0 0 0.33 0 0 
Soygerm 0 0 0 0 18 0 
Soygerm extract 0 0 0 0 0 1.78 
1. Vita-free casein ( Harlan/Teklad, Madison, WI) 
2. Vitamin mixture #400160 (Harlan/Teklad, Madison, WI) 
3. Mineral mixture #170910 (Harlan/Teklad, Madison, WI) 
4. Rice flour (Bioserve, Frenchtown, NJ). 
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Table 3. Plasma cholesterol levels (mmole/L) in male hamsters'"^ 
fed casein- or ISP-based diets with or without soy isoflavones 
Casein ISP ISP (-) Dadizein Soy 
germ 
Germ 
extract 
Total 
6.22±0.33' 5.18±0.30'' 4.93±0.29" 4.74±0.3l" 4.83±0.31" 4.77±0.24" 
HDL 3.01±0.18'' 2.71*0.20"" 2.79±0.15"" 2.50±0.16" 2.81±0.17"" 2.55±0.12"" 
LDL^ 3.21 ±0.23" 2.47*0.16" 2.14±0.I3" 2.24±0.17" 2.02±0.17" 2.22*0.17" 
LDL/HDL 1.10±0.ll" 0.95±0.06"" 0.7710.0.02"^ 0.87±0.03"' 0.72±0.03' 0.8810.06"^ 
Triglyceride 2.88±0.23" 2.50±0.18" 2.44±0.28" 2.67±0.17" 2.74±0.18' 2.56±0.22' 
1. Values represent means ± SEM, n=10; 
2. Within a row, means with different superscripts are different (P<0.05); 
3. Represents the VLDL+IDL+LDL fractions (by difference; Total - HDL). 
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Table 4. Plasma cholesterol level (mmole/L) in female hamsters' " fed 
Casein- or ISP-based diets with or without soy isoflavones 
Casein ISP rsp (-) Daidzein Soy 
germ 
Germ 
extract 
Total 5.61±0.27" 4.73±0.3l'^ 4.91^0.35"" 4.37*0.25"' 4.08*0.30' 4.28*0.23"^ 
HDL 2.1(^0.09" 2.70^0.21'" 2.82±0.35' 2.18*0.10" 2.32*0.25'" 2.13*0.16''" 
LDL^ 3.51±0.28" 2.03±0.2l'' 2.09±0.25^ 2.19±0.Il" 1.77*0.21" 2.16*0.11" 
LDL/HDL 1.72±0.18' O.SliO.ll" 0.84*0.11" L01±0.04" 0.83*0.11" 1.05*0.08" 
TAG L53±0.18' 1.12±0.12-''' LOSiO.n" l.26±0.14'"' 1.25*0.18"" 1.10*0.11"" 
1. Values represent means ± SEM, n=lO; 
2. Within a row. means with different superscripts are different (P<0.05); 
3. Represents the VLDL+IDL+LDL fractions (by differences: Total - HDL). 
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Table 5. Plasma isoflavone concentrations in hamsters (|iM)' ~ 
Male ISP ISP (-) Daidzein Soygerm Germ Extract 
Daidzein 1.4 - 0.4 2.3 -
Glycitein 1.2 - - 1.7 -
Genistein 0.8 - - 0.8 3.6 
Equol 
- - 1.6 0.5 -
Total 3.4 - 2.0 5.3 3.6 
Female ISP ISP (-) Daidzein Soygerm Germ Extract 
Daidzein - - 0.6 - -
Glycitein 
- - - -
-
Genistein - - - - 3.6 
Equol - - 4.0 - -
Total 
- - 4.6 - 3.6 
= not detected. 
• Minimal detection level: 0.4 jiM in plasma sample. 
127 
GENERAL CONCLUSIONS 
Soy isoflavones have attracted attention recently because these compounds have been 
associated with certain health beneficial effects such as prevention of cancer, lowering blood 
cholesterol levels and reduction of postmenopausal bone loss. Isoflavones have some 
important biological activities, including estrogenic, antiestrogenic, antioxidant and protein 
tyrosine kinase-inhibiting activities. 
Because of these important beneficial activities, the consumption of isoflavone-
containing foods is increasing dramatically. A good database is needed to provide public 
dietary information on soy isoflavones. There have been considerable efforts to quantify the 
isoflavone content in various food products. To perform an accurate and precise analysis, a 
good internal standard is very critical. However, to date, there has not been a good internal 
standard for soy isoflavone analysis. 2,4,4'-Trihydroxydeoxybenzoin (THB), the new 
internal standard we discovered for isoflavone analysis, has been demonstrated to be an 
excellent internal standard in the analysis. THB gives us the opportunity to do a better 
quality control job in isoflavone analysis and will be widely used in future isoflavone 
analysis, both in food and biological samples. A soy isoflavone database in the most widely 
used soy foods in U.S. has already been developed in our lab and will be available to the 
public in the near future. 
The estrogenic activity of daidzein and genistein had attracted great attention and may 
play significant roles in isoflavone's health beneficial effects. However, for the third 
isoflavone is soy, glycitein, no biological activities have been reported. Our study 
demonstrated that glycitein had estrogenic activity 3 times higher than genistein in the in vivo 
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mice uterine enlargement assay, but much lower than DES. Glycitein has the ability to bind 
to estrogen receptor in the in vitro estrogen receptor-binding assay. In addition to the 
demonstrated estrogenic activity of daidzein and genistein, we now have a more complete 
picture of all soy isoflavones' estrogenic activity. These estrogen-like activities may be very 
important in isoflavones' health protective activities. Although glycitein only accounts for 5 
to 10% of the total isoflavones in soybeans, its biological activity and possible health 
enhancing activities should not be neglected. It will be interesting to test the antioxidant 
activity of glycitein, as well as its ability to inhibit the protein tyrosine kinase activity. In 
addition, the effects of glycitein on the growth cancer cells need to be investigated. 
Soy protein's hypocholesterolemic effects have been reported in animal models as 
well as in human subjects. The factors that are responsible for this cholesterol lowering 
effects are still under investigation. Soy protein itself, soy saponins, soy phenolic acids, as 
well as soy isoflavones, have been proposed to be hypocholesterolemic. The 
hypocholesterolemic activity of daidzein proved in our study is the first direct evidence 
showing the relationship between soy isoflavones and soy's cholesterol lowering effects. 
The ability of isoflavone-fi-ee soy protein to lower plasma cholesterol in hamsters suggested 
that there were more than one active factor that are responsible for soy protein's reported 
hypocholesterolemic effects. Future studies need to be done to elucidate the mechanisms of 
isoflavone's cholesterol lowering effects. It will be very interesting to test the cholesterol 
lowering effects of genistein, glycitein or different combinations of isoflavones. How these 
isoflavones interact with the important steps in cholesterol metabolisms, including 
cholesterol synthesis and clearance, will be another interesting issue to look at. 
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The evidence to support isoflavone's beneficial effects is accumulating. People are 
more aware of these compounds in soy and the consumption of isoflavone-containing foods 
in rising. On important issue to be addressed is the possible side or toxic effects of these 
chemicals. Few studies have been performed to investigate the toxicity of soy isoflavones. 
Because of their estrogen-like activity, it is very important to investigate the possibilities of 
isoflavones to disturb the balance of human endocrine system. A thorough toxicology study 
on isoflavones, combine with a good isoflavone database in foods, will help us to establish a 
safe guideline for the intake of these phytochemicals. 
In order to fully understand the biological activities, the beneficial effects, as well as 
the possible toxic effects of isoflavones, a stable and inexpensive source of pure isoflavones 
is needed. Chemical synthesis of isoflavones is a practical way to obtain large amount of 
pure isoflavones. Chang et al. (1994) reported a simple procedure to synthesize genistein. 
Our modified method to chemically synthesize daidzein provides us a simple, fast method to 
produce large quantities of pure daidzein at relative low costs. However, no simple and high 
yield method to synthesize glycitein is available. Based on the synthesis of daidzein and 
genistein, it is very likely that a similar protocol may be developed. Cyclizing of the 
corresponding deoxybenzoin of glycitein to obtain pure glycitein seems promising and needs 
future investigation. 
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